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Spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disease 
characterized by degeneration of spinal cord alpha motor neurons (αMNs). It is caused by the homozygous 
deletion or mutation of the survival motor neuron 1 (SMN1) gene, resulting in reduced expression of SMN 
protein, which leads to αMN degeneration and muscle atrophy. A second gene, SMN2, contains a mutation 
that promotes exclusion of exon 7 and causes the SMN2 transcripts to generate a truncated, nonfunctional, 
form of SMN: the SMN∆7 protein. A recent treatment with antisense oligonucleotides (ASOs) has been 
developed for SMA – Nusinersen (Spinraza, BIOGEN), which works by promoting the inclusion of exon 
7 in SMN2 transcripts. 
In this work, we used the αMNs of the SMN∆7 mouse model of SMA to study the effects of 
Nusinersen in the behavior of Cajal bodies (CBs) and the cellular distribution of polyadenylated mRNAs. 
CBs are nuclear structures involved in RNA metabolism that can be disrupted in response to cellular stress 
in SMA αMNs. Moreover, an abnormal accumulation of polyadenylated mRNAs in nuclear granules 
(PARGs) have been previously shown in αMNs from the SMN∆7 mouse model of SMA. Notably, in our 
study we demonstrate that the treatment with Nusinersen, administered via intracerebroventricular 
injection, rescues growth curve and improves motor behavior in these mice. Importantly, Nusinersen also 
recovers the number of canonical CBs and reduces the abnormal accumulation of polyadenylated RNAs in 
nuclear granules or PARGs. Furthermore, the treatment with this ASO normalizes the expression of the 
pre-mRNAs encoding chondrolectin and choline acetyltransferase, two key factors for αMNs homeostasis.  
In light of these results, we propose that the mechanism of action of Nusinersen is partially mediated 
by the rescue of both CB biogenesis and the normal processing and distribution of polyadenylated mRNAs. 
It also becomes apparent that the rescue of SMN levels in the spinal cord has a beneficial effect on αMNs 
and skeletal myofibers, but the rescue of SMN expression in muscle is needed for the complete recovery 
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AAV – Adeno-associated Viruses 
ASO – Antisense Oligonucleotides 
BBB – Blood Brain Barrier 
CARM1 – Coactivator Associated Arginine Methyltransferase 1 
CBs – Cajal Bodies 
ChAT – Choline Acetyltransferase 
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PARGs – Polyadenylated RNA Granules 
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qRT-PCR – Quantitative reverse transcription polymerase chain reaction 
RNPs – Ribonucleoproteins 
- scaRNP – small Cajal Body-specific ribonucleoprotein 
- snoRNP – small nucleolar ribonucleoprotein 
- snRNP – small nuclear ribonucleoprotein 
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SDH – Succinate Dehydrogenase 
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SMA – Spinal Muscular Atrophy 
SMN protein – Survival Motor Neuron protein 
SMN1/SMN2 genes – Survival Motor Neuron 1/2 genes 
TA muscle – Tibialis anterior muscle 
TSL1/TSL2 – Terminal Stem Loop 1/2 
URC – U-rich clusters 
USPL1 – Ubiquitin-Specific Protease-Like 1 
WT animal – Wild Type animal 
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1. Spinal muscular atrophy 
1.1. Introduction  
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease, currently 
considered as the leading genetic cause of infant mortality. It is characterized by reduced levels of the 
Survival Motor Neuron (SMN) protein that lead to alpha motor neuron (αMNs) degeneration and death 
and, consequently, muscle atrophy 1–4. The αMNs are located in the anterior horn of the spinal cord, and 
they innervate muscle myofibers (Figure 1). Muscle atrophy leads to SMA’s characteristic clinical symptom 
– generalized progressive muscular weakness (Figure 1). This weakness is more pronounced in proximal 
muscles and, in severe SMA patients, intercostal muscles are weaker than the diaphragm which in most 
cases leads to respiratory complications leading to death 5.  
 
Despite αMNs being especially affected in SMA, SMN protein is ubiquitously expressed in all 
somatic cells with multitude of housekeeping and tissue-specific functions. Therefore, while the selective 
Figure 1. Distribution of the CNS (left), divided in bran and spinal cord. Cross-section of the spinal cord (middle) 
showing the localization of the αMNs in the anterior horn. On the top, the yellow αMNs  innervate the muscle fibers 
properly, maintaining the neuromuscular junctions. On the bottom, illustrating the SMA situation, the red αMNs are 
degenerated, and loss of the neuromuscular junction leads to denervation and atrophied muscle. 
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vulnerability of αMNs is a predominant feature in SMA, SMN deficit has been shown to also affect other 
organs such as skeletal muscle, liver, pancreas, spleen, blood vessels, and heart 6. Despite SMA being a 
systemic disease and involving several organs, the predominant clinical feature is the range of mobility a 
patient has, and the age of onset. Based on these criteria, the clinical spectrum ranges from early infant 
death to mild weakness in adulthood 7.  
SMN is a well conserved protein encoded by the Survival Motor Neuron 1 gene (SMN1) 2,3. Most 
vertebrates maintain a similar sequence, with a C-terminal YG box as the most conserved motif, from yeast 
to humans 2. This has permitted the use of various animal models in research, such as Drosophila melanogaster, 
Caenorhabditis elegans, zebrafish (Danio rerio), and mouse (Mus musculus) 2,4. In all organisms, total loss of SMN 
causes lethality, although the point of death depends on the amount of maternal SMN that each embryo 
receives. Thus, oviparous animals have more SMN left over from the mother and, therefore survive for 
slightly longer 4. Working with different models has the advantage of being able to identify both specific 
functions affected by specific mutations in animal SMA models like Drosophila, but also be able to see the 
systemic effect of those mutations in other animals like zebrafish or the mouse 4.  
1.2 Epidemiology and clinical features  
SMA was first described by Guido Werdnig (1844–1919) and Johann Hoffmann (1850–1919), but it 
wasn’t until 1995 that the genetic cause of SMA, the SMN1 gene deletion or mutation, was identified by 
Dr. Judith Melki and her team 8,9. SMA has a prevalence of about 1 case per 6000-10000 live births, and a 
carrier frequency of 1:35 to 1:50, depending on ethnicity. In humans, SMN1 gene has a paralogue, the 
SMN2 gene, that due to natural specific point mutations is not able to fully compensate for the loss of 
SMN1 10,11. The number of copies of SMN2 that any patient has, will determine disease severity. Clinically, 
SMA has been divided in five categories, according to the age of onset and the clinical course (Table 1) 5,7,12. 
Spinal muscular atrophy classification 
Type Age of onset Highest motor  function reached Age of death 
SMN2 gene  
copy number 
0 Prenatal Breathing dysfunction <1 month 1 
I 0-6 months Cannot sit <2 years 2 
II <18 months Cannot stand >2 years 3 
IIIa 18 months – 3 years Can walk Adulthood 3, 4 
IIIb >3 years Can walk Adulthood 3, 4 
IV >21 years Can walk Adulthood 4 or more 
Table 1. Spinal muscular atrophy classification. Based on Martínez, 2012 5. 
 
 SMA Type 0: is the most severe type of SMA, if very uncommon. It is a prenatal form of the 
disease, and it is fatal in utero or shortly after birth (<1 month). This type is very rare, and it has been defined 
by the following clinical features: paucity of movement in limbs, face and trunk, no suck, muscle atrophy, 
areflexia, congenital contractures, and requirement for mechanical ventilation support at birth 12. 
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 SMA Type I: also called the Werdnig-Hoffmann disease, is the severe form of SMA, and the most 
common. It starts shortly after birth. Children are never able to sit on their own, have impaired head control, 
weak cry and cough. The tongue may atrophy and show fasciculation. Muscle atrophy in the limbs and 
trunk is followed by atrophy in the intercostal muscles, leading to a bell-shaped trunk with chest wall 
collapse and abdominal protrusion. This all leads to early death around 6 months of age, associated with 
bulbar dysfunction and pulmonary complications. Three subtypes have been proposed: type Ia with 
neonatal onset, type Ib with post neonatal period onset, and type Ic, with later onset, and slightly milder 
symptoms during the first 6 months of life 7,9 (Figure 2). 
 SMA Type II: the intermediate form of SMA. It starts before 18 months of age, and the children 
are able to sit, sometimes independently. These children have delayed motor milestones, although they all 
can maintain a sitting position unsupported. They have bulbar weakness, so they struggle to eat and gain 
weight, cough, and clear tracheal secretion. They also have fine tremors in the hands and can develop 
kyphoscoliosis and joint contractures 7,9 (Figure 2). 
 SMA Type III: also called Kugelberg-Welander disease or juvenile SMA. These patients are 
affected after 2 years of age, and all achieve independent walking. Some then lose this ability, others 
maintain it. They can develop scoliosis, muscle ache and joint overuse symptoms, but swallowing 
difficulties, cough and nocturnal hypoventilation are less common. Within this group, some 
subclassifications have been proposed. Type IIIa patients have an age of onset before 3 years old, whereas 
type IIIb patients have their onset after that age. It is more common for type IIIa SMA patients to maintain 
the ability to walk past the age of 40 7,9 (Figure 2). 
 SMA Type IV: adult-onset form of the disease, usually in the second or third decade of life. It 
presents mild proximal muscle weakness, without respiratory or gastrointestinal problems, and a normal 
life expectancy 7,9 
Figure 2. Photographs of SMA types I, II and III patients. In type I the child is seen unable to support 
themselves, and they exhibit a bell-shaped trunk with collapsed chest and protruding abdomen. In type II, the child 
is unable to walk, may have difficulty sitting. In type III, the symptoms are much milder, but the patient could still 




2. Molecular basis of SMA 
2.1. The SMN1 and SMN2 genes 
In 1995, Dr. Judith Melki and her team identified and determined the DNA sequence of the SMN1 
gene located in the long arm of chromosome 5 (5q11.2-p13.3) 13,14. They demonstrated that, in 95% of the 
individuals with SMA, this gene was deleted or mutated 10. Melki’s team also identified that humans have a 
paralogue gene, SMN2, an inverted centromeric duplication of SMN1 15.   
The SMN1 and SMN2 genes are nearly identical and encode a pre-mRNA composed of 9 exons, 
from which exon 8, the longest, is the 3’ UTR. The rest, exon 1, 2A, 2B, 3, 4, 5, 6 and 7, code for the 
functional SMN protein 16. However, SMN2 and SMN1 genes have an essential functional difference: a C-
to-T (840C>T) silent point mutation, located in the +6 position of exon 7. This nucleotide change favors, 
in 90% of the cases, an alternative splicing of the SMN2 pre-mRNA. As a result, the end product SMN2 
mRNA loses exon 7 during splicing events and is translated into a truncated non-functional isoform of 
SMN known as SMNΔ7 protein 4. This truncated protein is unable to self-oligomerize, and is highly 
unstable in comparison to SMN, so it is degraded quickly by the proteasome 3 (Figure 3). In SMA, the low 
levels of SMN protein are due to the deletion or mutation in SMN1 and, unfortunately, the presence of the 
SMN2 gene cannot rescue the phenotype since only a small amount of functional SMN (10%) is produced 
by this gene. This is the main reason why the number of SMN2 copies matters in terms of disease severity 
and clinical prognosis. 
Figure 3. Comparative graphic of the full-length protein yield of genes SMN1 vs SMN2. Due to a C-to-T mutation 
(reversed since SMN2 is an inverted copy), the pre-mRNA in SMA undergoes alternative splicing in 90% of the transcripts 
(blue). Thus, the main product after translation is the non-functional SMN∆7, which becomes degraded quickly, while in 
the normal situation the constitutive splicing into functional SMN (green) is almost 100% of the yield. In SMA, the small 
amount of functional SMN, product of SMN2, is not enough to compensate for the loss of all SMN encoded by the SMN1 
gene. For this reason, patients with more than one copy of SMN2 can have milder symptoms, leading to the different types 
of SMA patients described earlier.  
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2.2. Mechanisms of alternative splicing of the SMN2 exon 7 
Splicing is controlled by elements that can be located in the immediacies of their target genes. Cis-
regulatory elements, often serve as binding sites for one or more factors, while Trans-regulatory elements 
can regulate distant genes. The specific sequence and location of cis-elements can have positive or negative 
effects depending on the specific factor bound and its splicing functional activity. Thus, exonic splicing 
enhancers (ESEs) are factors that stimulate splicing and are often required for efficient intron removal, 
whereas exonic splicing silencers (ESSs) inhibit splicing. In humans, the observed difference in exon 7 
splicing between SMN1 and SMN2 is controlled by many cis-elements, with more than 40 splicing factors 
known so far. The preferential skipping found in SMN2 seems to be the result of a combination of multiple 
negative interactions upon the 5´ and 3´ splicing sites 16.  
 In the case of SMN2 exon 7 splicing, herein we will focus on those cis-regulatory elements that are 
located within exon 7, or in the immediately downstream intron. Thus, SMN2 pre-mRNA contains, at the 
beginning of exon 7, an “Exint” (extended inhibitory) context. In particular, the C-to-T transition in the 
+6 position within SMN2 exon 7 induces a terminal stem loop (TSL1) that has been proven to play an 
inhibitory role, preventing exon 7 inclusion by interfering with the binding of splicing factors at the 3´ splice 
site (3´ss) of exon 7 (Figure 4). At middle of exon 7, there are overlapping positive elements, while at the 
end, there is a cluster of negative cis-elements, including a second terminal stem loop (TSL2) near the 5´ 
splice site (5´ss) of exon 7 16 (Figure 4).  
 
Figure 4. Scheme of exon 7 and intron 7’s sequence in SMN2 pre-mRNA. Positive splicing elements in green 
and negative elements in red. Exonic and intronic sequences are written with uppercase and lowercase letters 
respectively. The blue U and g corresponds with the most common point mutation in SMA, that create additional 
binding sites for hnRNP A1/A2 (negative). Within the exon there are three regulatory elements: an extinct element 
(inhibitory), a cluster of positive overlapping elements, and the terminal stem-loop structure, TSL2, at the end 
(inhibitory). Within the intron, the ISS-N1 (silencer), contains two hnRNP A1/A2 binding sites, and URCs (positive). 




Located immediately downstream of exon 7 there is an intronic splicing silencer N1 (ISS-N1). ISS-
N1, a 14 bp downstream of the 5´ss of exon 7 (positions 10th to 24th of intron 7), is a complex regulatory 
element encompassing overlapping negative motifs functionally implicated in the sequestration of the 5´ss. 
Other elements found within intron 7 are U-rich clusters (URCs), positive elements that bind TIA1, an 
RNA-binding protein that stimulates exon inclusion by recruiting U1 snRNP to the 5’ss (Figure 4).  
In SMN2 pre-mRNA, these URCs get sequestered into internal-stem structures formed through 
long-distance interactions. One of such structures known as ISTL1 has a 5’ strand that overlaps with the 
5’ss of exon 7 and the first position of ISS-N1, strengthening the TSL2, and a 3’ strand that overlaps with 
another negative element (ISS-N2), located downstream in intron 7 16-17.  
2.3. The SMN protein and the SMN-complex 
Human SMN is a protein with 294 amino acids and has several interacting motifs, including: a 
basic/lysine-rich domain, a Tudor domain, a proline-rich domain and a tyrosine/glycine-rich region or YG-
box (Figure 5A) 3. 
The basic/lysine-rich region is encoded by exon 2 and has been found to be the interaction site with 
RNAs, through a nucleic acid-binding domain. This N-terminal region is also the binding site with the 
Gemin-2 protein 3. Through the highly conserved TUDOR domain, SMN binds to the RNA-binding 
proteins Sm, which are the major constituents of the spliceosome. The Tudor domain is also responsible 
for the interaction of SMN with coilin, the main structural protein of the nuclear Cajal bodies (CBs). 
Furthermore, the Tudor domain has a SUMO-interacting motif (SIM), whose non-covalent SUMOylation 
is key for Sm protein binding and for CB assembly 3. These are ubiquitous structures in mammalian cells 
whose number correlate with cell body size and transcriptional activity. CBs are involved in the biogenesis 
of essential factors required for the processing of pre-mRNAs and pre-rRNAs 18. At the C-terminal, the 
SMN protein has a proline-rich sequence that binds Profilin, a protein implicated in the regulation of actin 
dynamics, and the YG-box, a motif of 16 amino acids that facilitates SMN self-oligomerization, which is 
essential for protein stability and subcellular localization of SMN 2,19. A recent study has demonstrated that 
monomeric SMN exposes a small degradation sequence – also called a degron – present within the YG 
box. This degron allows SMN binding to the SCFSlmb ubiquitin E3 ligase prompting its degradation 20. 
Deficit in SMN oligomerization directly correlates with the severity of SMA. Therefore, SMN is normally 
found as a homopolymer, complexed to the proteins Gemin2-8 and Unrip to form the so-called "SMN 
complex" 4 (Figure 5B).  
Functional SMN protein, as part of the SMN complex, has essential housekeeping functions for cell 
survival. Among these, some functions have been proposed to have a bigger role in certain cell populations, 
such as MNs or myocytes, hence their specific affectation in SMA. Among its functions takes particular 
relevance the assembly of different categories of ribonucleoproteins (RNPs) (Figure 5C). The most well-
studied, is its involvement in the assembly of spliceosomal snRNP, and since then it has been found that it 
participates in almost every step of mRNA metabolism 19 (Figure 5D). Overall, SMN main functions 
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include pre-mRNA splicing, histone mRNA 3´end processing, snoRNP biogenesis or mRNA transport 
that will be briefly described next. SMN has also been described to play a critical role in cytoskeleton 
homeostasis, including endocytosis and autophagy 2–4,8,21.  
 
2.3.1. SMN Functions: Assembly of spliceosomal snRNPs and pre-mRNA splicing 
Splicing, the process by which different proteins can be formed from a single mRNA transcript, is 
mediated by the function of spliceosomal snRNPs. These snRNPs are formed by a single U-rich small 
nuclear RNA (U1, U2, U4, U5, U11 or U12-snRNA), and a heptameric ring of Sm proteins, through a 
multi-step process mediated by the SMN complex (Figure 5) 19. The U-snRNAs are a group of abundant, 
non-coding, non-polyadenylated transcripts that carry out their functions in the nucleoplasm 22. They can 
be divided in two classes, Sm and Sm-like, depending on their sequence and the proteins with which they 
interact 22.  
The SMN complex, binds to these U-snRNAs after they leave the nucleus, acting as a chaperone 
facilitating the binding of the U-snRNA to the specific Sm protein core 2,3. The Sm core is not assembled 
previously, instead, the Sm proteins form heterodimeric or heterotrimeric subcomplexes. These then only 
bind to their RNA target in presence of SMN complex, which is thought to add specificity and act as a 
catalytic element for the reaction (Figure 6, step 1) 22. The SMN complex stays with the snRNA while it 
Figure 5. Overview of SMN protein’s domains (A), which allow it to self-oligomerize and bind to other 
proteins, and its localization within the SMN complex (B), where it binds with the Gemin proteins and UNRIP. 
The SMN complex then goes on to bind a multitude of proteins and RNAs (C) as it facilitates their assembly 
into various elements of the protein synthesis machinery. This implicates SMN in many housekeeping 







undergoes hypermethylation of its m7G cap, forming the TMG cap, and the trimming of its 3’ end, 
processes required before entering the nucleus.  
It is noteworthy that the SMN complex binds to the snRNA through the protein Gemin5, which 
recognizes the Sm site in the sequence. Gemin2, another member of the SMN complex, binds to five of 
the seven Sm proteins, helping them acquire the correct shape and orientation needed to assemble the 
snRNP 22 (Figure 6, step 2). Once assembled, the TMG cap of the U-snRNA and the SMN complex itself 
act as a nuclear import signal, and the whole snRNP gets reimported to the nucleus via interaction with 
importin-α 3 (Figure 6, step 3). Once in the nucleus, the SMN complex binds to the protein coilin, 
structural component of the CBs, to direct the localization of the snRNP to the interior of the CB.  Here 
the U-snRNA will acquire snRNP-specific proteins and will be modified at nucleotide level. These 
modifications, guided by scaRNPs (small CB-specific RNPs), are essential maturation steps before the 
snRNP can become part of the spliceosome (Figure 6, step 4) 2,23. 
Functional spliceosomes are large and complex molecular machine formed by five mature snRNPs 
and more than 80 RNA-binding proteins (Figure 6, step 5). During splicing, introns will be cleaved from 
a transcribed pre-mRNAs, and through combination of the exons a particular mRNA isoforms will be 
obtained 2–4,21. Alternative splicing (the re-combination of different exons) is the major source of genetic 
diversity in eukaryotes. 
Figure 6. SMN’s role in snRNP assembly. (1) The SMN complex binds to the U snRNA and the Sm ring once 
they are in the cytoplasm, (2) acting as a chaperone and facilitating their assembly into snRNPs that then (3) get 
reimported into the nucleus. (4) Once there they undergo more modifications in the CB, thanks to the scaRNAs, and 
the SMN complex dissociates from them. (5) Finally, the mature snRNPs become part of the spliceosome and are 
able to bind to pre-mRNAs. 
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2.3.2. SMN Functions: Biogenesis of snoRNPs and rRNA modification 
Small nucleolar RNPs (snoRNPs) are a class of RNPs that are associated with the post-transcriptional 
processing of non-coding RNAs such as ribosomal RNAs through methylation and pseudourydilation 2,3. 
They are formed by a small guide nucleolar RNA (snoRNA) and specific protein factors. Among these 
protein factors, some have been found to interact with SMN, such as GAR1 and Fibrillarin 2. The snoRNAs 
can be separated into two categories. Depending on the motifs found in their sequences they can have a 
H/ACA box or a C/D box, which guide pseudouridylation and 2-O-methylation, respectively. Both of 
these types rely on their secondary structure to bring close together the different parts of their motifs (H 
box and ACA box, C box and D box). This structure is also required for them to interact with the protein 
components of snoRNPs, as well as their target rRNA 2. 
Another subset of snoRNPs are the so-called scaRNPs. As mentioned before, they are located in 
CBs, where they guide the same post-translational modifications to target nucleotides within U-snRNAs. 
The CB localization signal present in scaRNAs is a CAB box sequence, which is specifically recognized by 
the WRAP53 protein. Moreover, both snoRNPs and scaRNPs are transcribed by the RNA polymerase II23. 
SMN has been shown to interact with WRAP53 and RNA pol II, further confirming that, in SMA, snoRNP 
localization can be impaired 2. 
It has been proposed that CBs play a role in snoRNA and scaRNA maturation, since they are 
concentrated in CBs along with their associated proteins. It has also been observed that uncapped snoRNAs 
and scaRNAs may mature in CBs, though their transport into CBs remains unknown. In the case of 
scaRNAs, WRAP53 has being demonstrated to be involved in their transport to the CB 23. It is particularly 
relevant, the fact that in SMA patients there is a strong depletion of scaRNPs which can in turn affect 
snoRNP biogenesis and therefore nucleolar dysfunction 2. 
2.3.3. SMN Functions: Assembly of U7 snRNP and histone mRNA 3’ processing  
The 3’ end of histone mRNAs requires a specific processing that is mediated by the U7-snRNP. U7-
snRNP has a similar structure to spliceosomal snRNPs, however, instead of SmD1 and SmD2 proteins, its 
heptameric ring contains Sm-like proteins. The SMN complex that facilitates this snRNP assembly has been 
proposed to be slightly different. Therefore, in SMA, SMN deficiency would lead to accumulation of U7-
snRNA unable to form the functional U7-snRNP, and to the incorrect processing of the 3’end of histone 
mRNAs, affecting in turn the structure of chromatin 2,3. 
2.3.4. SMN Functions: mRNA transport and translation 
SMN has been shown to interact with β-actin mRNAs in neuronal processes and growth cones 24. 
As mentioned before, SMN forms the SMN complex with the Gemin proteins and Unrip. However, it has 
been found that, in motor axons, it does not fully co-localize with Gemin2, indicating that SMN protein 
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might be involved in functions unrelated to snRNP assembly 25. In fact, SMN protein has been found to 
change its primary localization from mainly nuclear during development to cytoplasmic, and then axonal, 
suggesting a potential role for SMN in axons during axonal growth 26. Using type I SMA mouse models, 
hnRNP-R has been studied in relation to axon growth. hnRNP-R is an RNA-binding protein that has been 
previously found to interact with the β-actin mRNA and with the SMN protein 24,27. β-actin plays a main 
role in axonal growth, as it is part of the cytoskeleton, and its accumulation in the growth cone depends on 
its own mRNA correct transport. Interestingly, both β-actin and hnRNP-R expression have been found to 
be lower in SMN deficient neurons, correlating with a three times diminished growth cone area in cells 
isolated from the lumbar spinal cord 24. On this basis, SMN is considered to be part of the regulation and 
localization of β-actin, as well as axonal growth in motor neurons 24.  
SMN can also interact with other RNA-binding proteins that traffic proteins in MNs as HuD and 
IMP1. These two proteins have been found to transport more than 200 mRNAs that have been identified 
as potential targets for SMN trafficking 2. In fact, in cultured cells from a severe SMA mouse model, 
overexpression of HuD and IMP1 rescues GAP43 mRNA and protein levels, and axon growth defects 28. 
There is an increasing number of evidences that point toward SMN protein having a role in mRNA 
translation as well 3. One proposed mechanism is that SMN has been shown to associate to polyribosomes. 
Using in vitro Luciferase reporter assays, it has being found that there was a dose-dependent reduction in 
translation efficiency directly related to SMN protein level 29. Moreover, SMN may influence the Dicer-
miRNA pathway, which is involved in nerve regeneration and axon outgrowth, as miRNAs, such as miR-
9, are affected in SMA30. SMN may also control the mTOR pathway through its interaction with miRNAs, 
in particular miR-183 2,31. This has been studied both in the Taiwanese mouse model and in SMA patient-
derived fibroblasts, where the pathway was knocked down 31. Additionally, when a negative regulator of 
the mTOR pathway is knocked down, there is an increase in axonal growth and cell survival, and β-actin 
levels in the axon are restored 32. Finally, an in vivo study that looked at the transcriptome versus the 
translatome with next-generation sequencing, has found that there are defects in the biogenesis of 
ribosomes, which could account for the defects in translation as well 3. 
As a final note, the defects in translation are only amplified by the lack of RNA-binding proteins, 
and even properly translated proteins with other functions. For example, SMN regulates the translation of 
coactivator associated arginine methyltransferase 1 (CARM1), a protein implicated in transcription, splicing 
and autophagy 2. CARM1 is consistently upregulated in SMA mouse models and SMA type I patients, since 
the lack of SMN increases CARM1 levels, and this in turn causes aberrant transcription of other proteins, 
such as the Ubiquitin-Specific Protease-Like 1 (USPL1) gene, a gene that shows an increased inclusion of 





3. Neuromuscular pathophysiology of SMA 
As mentioned before, SMA is a genetic disorder classified as a neuromuscular disorder and a motor 
neuron disease (MND). It is characterized by degeneration of αMN in the spinal cord that affects the 
control of voluntary muscle movement. However, the structural and functional cellular deficits that lead to 
the impairment of the neuromuscular system remain poorly defined.  
3.1. The alpha motor neurons 
Anatomically, the spinal cord is a cylindrical structure made of nervous tissue, located in the vertebral 
cavity. There are 31 pairs of spinal nerves come out of it to innervate skeletal muscle, smooth muscle, and 
glands. The spinal cord is enlarged at the cervical region, from which sensitivity and motor actions are 
signaled to the upper limbs, and at the lumbo-sacra region, responsible for sending the same information 
to the lower limbs. It maintains a continuous cross section along its length, formed by grey matter and 
white matter, arranged in a characteristic shape of a butterfly (grey matter) encased in the white matter 
around it. The anterior horns (ventral) are rounder and wider and contain the MNs 33,34 (Figure 7). 
In humans, there are two types of motor neurons: αMNs, which have wider axonal diameter and 
innervate extrafusal fibers, and γMNs, which are thinner and innervate intrafusal fibers. The extrafusal 
fibers are the standard skeletal muscle fibers also known as myofibers that generate tension by contracting, 
which leads to movement. The connection of an αMN with the myofibers that it innervates is what is called 
a motor unit 35. The intrafusal fibers are very small-diameter fibers that act as proprioceptors, detecting 
changes in muscle length (muscle tone). They are sheathed by connective tissue, apart from the rest of the 
fibers. They do not contract in the same way as extrafusal fibers, instead, the central part of them merely 
stretches when the two ends contract 33,35. 
Both αMNs and γMNs have subtypes. For the γMNs, there are two types, differentiated by the effect 
they have on primary and secondary sensory endings, that is, whether they stimulate endings capable of 
sensing dynamic stimuli or static stimuli. In the case of αMNs, the differences stem from the resistance of 
the motor unit to fatigue, and the presence or absence of a “sag” in the tension generated under a 
continuous stimulus 36. This leads to three types of motor units: (i) type FF (fast contracting fatigable motor 
units), which has big-diameter type IIb myofibers, the sag, and the highest number of myofibers per motor 
unit; ii) type FFR (fast contracting fatigue-resistant motor units), which has medium-diameter type IIa 
myofibers and the sag; and iii) type SFR (slow contracting fatigue-resistant motor units), which has small-




3.2. The skeletal muscle fibers 
A skeletal muscle cell, as mentioned above commonly referred to as a myofiber, is a syncytium 
formed by the fusion of myoblasts to form a single one with multiple nuclei. A muscle is formed by these 
myofibers, held together by conjunctive tissue, the endomysium, which contains the nerve fibers and blood 
vessels 35. 
Just like there are three types of motor units, there are also three types of myofibers: Type I 
myofibers or slow oxidative fibers. They are small in diameter, appear red, and have a high content of 
mitochondria, myoglobin and cytochrome complexes. They contract slowly and are fatigue resistant, 
though they generate less tension than the other types. Type IIa myofibers or fast glycolytic oxidative 
fibers, are the intermediate fibers seen in fresh tissue. They have many mitochondria and hemoglobin and 
high amounts of glycogen so they can go through anaerobic glycolysis. They contract quickly and are fatigue 
resistant. Type IIb myofibers or fast glycolytic fibers, are big, pale pink fibers. They have less myoglobin 
and mitochondria than the other types, but they store glycogen and show a high enzymatic glycolytic 
activity. They generate great muscular tension, but get fatigued quickly due to lactic acid production.35 
The myofiber is composed of bundles of cylindrical myofibrils arranged in parallel to the longitudinal 
axis of the fiber. Myofibrils, in turn, are composed of myosin myofilaments (thick filaments) and actin 
myofilaments (thin filaments) which are spatially ordered in the A-band (anisotropic) and I-band (isotropic) 
forming a cross-striation pattern. Each I-band is bisected by a transverse line, the Z-disc, enriched in α-
actinin. The segment of the myofibril between two successive Z-discs is called a sarcomere, which has 
typically 2-3 µm in length in a relaxed muscle and represents the functional unit of the myofiber (Figure 
8A). The parallel and ordered disposition of the myosin and actin myofilaments in a myofiber produces 
transversal A- and I-bands which give the name of striated to the muscle, due to the dark and light band 
Figure 7. Types of MNs and the different fibers they innervate. αMNs innervate extrafusal myofibers, 
being differentiated in three subtypes depending on the resistance to fatigue and the presence of a sag in the 
depolarization response, which translates to a faster movement: Fast/fatigable fibers (blue), fast/fatigue-resistant 
fibers (purple), and slow/fatigue-resistant (green). αMNs innervate intrafusal fibers, acting as a propioceptor of 
the changes in length (muscle tone). 
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pattern when observed by electron microscopy. A-bands are covered by both types of myofibrils and appear 
as dark highly electron-dense bands. I-bands are only covered by actin thin myofilaments (I band) and 
appear as lighter, less electron-dense bands. The A-band has a central sub-band only covered by myosin 
filaments during muscle relaxation called the H-band, which creates a thin linear density called the M-line 
at the middle of each A-band  (Figure 8). During muscle contraction, both the I band and the H band 
become shorter, but the A band stays the same 35. 
A recent study from our laboratory has demonstrated the precise localization of SMN in the human 
sarcomere 6. Sarcomeric huSMN is localized to the titin-positive M-band and actin-positive I-band, and 
accumulates in SMN-positive granules that are flanking the Z-discs. Co-IP assays further revealed that SMN 
interacts with the molecular components of actomyosin filaments and with other sarcomeric proteins. 
 
3.3. SMN-dependent mechanisms implicated in SMA pathogenesis 
In αMNs under normal conditions, SMN localizes to the cytoplasm and the nucleus. In the 
cytoplasm it forms the SMN complex with other proteins, where it participates in the biogenesis of snRNPs 
and mRNA transport, among other functions. As we have previously mentioned, in the nucleus, the SMN 
complex accumulates in CBs, where is involved in the biogenesis of both snRNPs and snoRNPs. It also 
accumulates in coilin-negative gems (for Gemini of CBs), whose function is uncertain. SMN is also found 
in the MN axon and is an integral sarcomeric component within the myofibers (Figure 9, left) 37. 
In type I SMA, approximately 65% of αMNs are lost, and the remaining ones show severe disruption 
of the protein synthesis machinery, showing chromatolytic somas and eccentric nuclei 37. At nuclear level, 
the somas with eccentric nuclei often lack large CBs and, contrary to healthy αMNs, do not concentrate 
SMN, snRNPs nor snoRNPs 37 (Figure 9, right). The absence of nuclear SMN implicates potential defects 
in the maturation of spliceosomal snRNPs in CBs, which is one of the proposed SMA pathogenesis main 
mechanisms: the SMN-dependent mRNA processing dysfunction 9,38. Nowadays, the dysfunction of 
Figure 8. A. Electron microscopy 
image of a sarcomere, labeled with the position 
of the I and A bands, as well as the Z-disc and 
M-band in each respectively. The paralell 
distribution of the myofilaments is also visible. 
B. Graphic representation of the same 
structure, where the basic shape of the proteins 
can be seen. In green and yellow respectively, 
myosin and actin are represented. They are 
displayed parallel to one another and bound to 
the Z-disc, composed of α-actinin (blue). At 





RNA metabolism has enabled to classify SMA as a RNAopathy, although it could also be considered a 
spliceopathy 39.  
Beyond these nuclear defects, SMA αMNs receive fewer glutamatergic synaptic inputs from 
proprioceptive sensory neurons and interneurons 9. The axon, as explained previously, presents outgrowth 
defects since the transport of one of its main components, β-actin mRNA, is impaired, as is the transport 
of many others mRNAs – thus impeding proper localization and translation of specific mRNAs 38. Not 
only that, but the neuromuscular junction (NMJ) - the chemical synapse between an MNs and a muscle 
fiber - shows several defects. These include accumulation of presynaptic neurofilaments, reduced synaptic 
vesicle content, impaired synaptic transmission, alterations in intracellular calcium homeostasis, defective 
clustering of Cav2.2 channels in MN terminals, defective postsynaptic acetylcholine receptor clustering at 
the sarcolemma, and defective motor endplate development 9,40. All of these defects in the NMJ lead to 
denervation of the myofiber causing muscular atrophy 9, 40 (Figure 9).  
At myofiber level, our own data suggest that SMN deficit causes primary effects independent of the 
neurogenic myopathy. Thus, in human type I SMA muscle low levels of SMN protein have a profound 
impact in the normal sarcomeric architecture, resulting in the disruption of myofibrils and overcontracted 
minisarcomeres in innervated hypertrophied myofibers 6. 
 
Figure 9. Functions of SMN within the motor unit. In a control motor unit, SMN has functions all across 
both cells involved, and within the NMJ. In a SMA motor unit, the lack of SMN protein leads to reduced ability to 
perform functional splicing and mRNA maturation, leading to abnormal expression of multiple proteins that affect 
translation, motor axon outgrowth (due to low actin expression), myelination deficits, abnormal NMJ morphology 
with defects in vesicle release, and denervation of the muscle fiber. As for the myofiber, the low levels of SMN lead 
to a reduced fiber diameter, and myotube formation deficits. Adapted from Boyer et al, 2010.  
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4. Current therapies for SMA  
Because SMA is a monogenic disease, largely caused by the lack of SMN protein, the search for a 
cure has classically being focused on increasing protein levels to match the physiological ones. These can 
be done by improving full-length SMN2 mRNA expression 21,41. To do this, there have been various 
approaches, from activating enhancers, to increasing exon 7 inclusion, through stabilizing SMN protein or 
SMN2 mRNA, and the gene therapy 21. Each of these approaches have certain disadvantages, such as (i) 
the small window of action in the neonatal period, since treatment should be administer before the clinical 
symptoms of SMA appear; (ii) the difficulty of administering the treatment intrathecally (CNS), because of 
the restrictive properties of blood-brain barrier (BBB) and, (iii) the lack of SMN level recovery in the 
peripheral tissues, since the drug only reaches the CNS 42. For all these reasons, classic approaches need to 
be accounted together with newer approaches.  
4.1 Small molecules-based treatments  
A series of small molecules, targeting the increase of SMN2 gene expression, are being developed for 
SMA therapy. They are administered orally, which is an advantage over the other therapies, though it is 
possible that they might not be able to cross the BBB 21. The first type identified were Quinazoline 
derivatives, which inhibit the RNA decapping scavenger enzyme DcpS, in turn activating SMN2 expression 
9. However, they were found to only have moderate effects on SMA, so other alternatives have been sought. 
Currently, although their action mechanism is poorly understood, these small molecules seem to be highly 
specific to SMN 9. These novel SMN-independent therapies are focused on complementing classic therapies 
during the later phases of the disease and can be divided into two categories 21:  
CNS-targeting molecules, as the cholesterol-like molecule called Olesoxime, the only one drug 
currently being tested in clinical trials. It acts on the outer mitochondrial membrane in response to oxidative 
stress. It is administered orally, and has been shown to have a neuroprotector effect; however, it has only 
managed to achieve stabilizing effects considering secondary objectives of treatment 21,41. Other targets 
being considered for potential combinatorial therapies are the protein Chondrolectin (Chodl), a potential 
modifier of axonal integrity, and Stasimon (or Tmem41b in mammals), which has a role in synaptic 
transmission 41.  
Non-CNS-targeting molecules are being tested since there is increasing evidences that SMA 
pathological mechanisms are not limited to αMNs. Therefore, therapies aimed exclusively toward the CNS 
might be insufficient, especially in type I SMA, where the SMN deficit is more pronounced 21. So far, only 
targets in skeletal muscle are being studied, as this is the second most affected tissue in SMA. CK-2127107 
is a drug already in phase 2 trials with SMA patients, which is a skeletal troponin activator. It has already 
been classified by the FDA as an orphan drug for SMA, despite the fact that it was developed for a rat 
model of heart failure, and tried in phase 1 as such 41. Other targets that are being considered are the 
myostatin-follistatin pathway, and the actin dynamics regulation pathways 41. Myostatin negatively regulates 
muscle growth, with follistatin inhibiting it, however, despite having several clinical trials in other diseases, 
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it is unclear whether it is affected in the same way in SMA yet. In the case of actin dynamic regulation 
pathways, both the ROCK-RhoA signaling and Plastin3 protein have been found to be involved in SMA 
pathogenesis, so those are also being considered as targets 41. 
4.2. Gene therapy 
SMA is an ideal candidate for gene therapy for a variety of reasons, among them: (i) type I SMA is 
lethal if left untreated, (ii) it has a specific genetic and cellular target (SMN1 in the anterior horn of the 
spinal cord), (iii) SMN overexpression is well tolerated, (iv) there are animal and cellular models known well 
enough to be used in clinical trials, (v) the length of SMN’s cDNA can be used in vectors, and (vi) gene 
therapy can be used to alter SMN splicing and increase SMN levels 21. The gene therapy focuses not on 
modifying the SMN2 gene expression, but rather, in recovering the gene SMN1. To this effect, a copy of 
the SMN1 human gene is introduced exogenously via a viral vector.  
One example of viral vectors are the adeno-associated viruses (AAV), which have been “engineered 
from a nonpathogenic, naturally nonreplicating parvovirus” 43. These vectors have been demonstrated to 
be safe in humans in the late 90s and have been used since for various diseases. They can show specific 
tropism to certain tissues, however, since they do not integrate with the host DNA, they are not ideal 
vectors for cells with high cellular turnover. In the case of SMA, however, and in other diseases with 
neurons, the effect of the vector has been shown to last for up to ten years 43.  
AVXS-101, previously scAAV9.CB.SMN, carries DNA-encoding human SMN 43,44. It has been 
through clinical trials in various models including large animals, and when tried in human patients, it has 
showed great improvements in motor milestones as well as survival. Moreover, the treatment seems safe, 
with rather occasional adverse events that are treatable 43,45. The FDA has already classified it as an orphan 
drug for all types of SMA 43. 
The main advantage of gene therapy is the administration method, as this only requires a single 
intravenous dose 21,44. On the other hand, gene therapy runs the risk of the vector not being easy enough 
to produce at a large enough scale to treat patients efficiently 43. Finally, as viral vectors are not yet 
commonplace as treatments, hospital staff might require specific training, and there might be safety 
concerns yet to be found 44. 
4.3. ASOs-based therapies 
Since all SMA patients keep at least one copy of SMN2, and the number of copies is inversely 
proportional to the severity of the disease, many types of therapies approaches have focused on increasing 
the expression of the functional isoform of the SMN2 gene. One such approach is the use of antisense 
oligonucleotides (ASOs) to promote exon 7 inclusion 1,16,21. 
ASOs are short, single-stranded, synthetic oligonucleotide chains, that can selectively bind to, and 
modify the expression of, its target pre-mRNA 21,43. Nusinersen (Spinraza™, BIOGEN), approved by the 
FDA in December 2016, is an oligonucleotide which has chemical modifications – such as a 
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phosphorothioate backbone, and methoxyethyl modifications – to enhance its stability 16,43. It binds to the 
SMN2 pre-mRNA to match the ISS-N1 silencer in intron 7. In doing so, it displaces negative splicing 
factors such as hnRNP A1/A2, allowing the interaction with U1 snRNP, which promotes exon 7 inclusion, 




ISS-N1 has become the most attractive target, as it is an accessible intronic sequence and thus will 
not cause interference with the protein coding transcript. Targeting it with ASOs has demonstrated its 
effectiveness even at very low doses, however, because ASOs cannot cross the BBB, it has to be 
administered intrathecally 16,43. In clinical trials, Nusinersen has succeeded in improving life expectancy of 
the type I SMA patients – raising it by two years after treatment started, while untreated patients would 
have died before that. Moreover, Nusinersen improves motor function, reaching milestones typical of 
milder forms of SMA 42,43,46. On top of that, ASOs are known to be stable inside the CNS for months, and 
have little to no toxicity 9. However, Nusinersen has not achieved complete motor function, and there are 
several potential limitations to its use, such as the difficulty of administering the treatment to some patients 
with severe spine conditions, frequency of dosing, or the cost of the treatment itself 43. There have been 
studies investigating whether administering the drug before symptom onset would help achieve even better 
results, but this has not been the case. While the newer treatment protocols of this drug may very well solve 
some of these problems – for example, if it became possible to administer intravenously 44 – this calls for 
the development of other therapies, whether SMN augmentation-based or not, in order to improve therapy 
outcomes 42. 
 
Figure 10. Method of action of Nusinersen (Spinraza™, BIOGEN) for exon 7 splicing correction. In SMN2 
normally the ISS-N1 would be involved in sequestering the 5’ss of exon 7 (in red), impeding its inclusion. Nusinersen 
(in pink in the figure), once administered intracerebroventricularly binds to this silencer, causing structural 
rearrangements and displacing the negative factors that could previously bind to it (such as hnRNP A1/A2B1, in 
purple in the figure). This causes the disruption not only of ISS-N1, but also other elements such as TSL3 and ISTL1 
(not shown). As a result of these rearrangements, binding of TIA1 (green) becomes accessible, which in turns 
increases the recruitment of U1 snRNP (light purple) to the 5’ss of exon 7, promoting its inclusion. Figure based in 
Singh and Singh, 2018. 
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All the three SMA therapy methods explained above have specific limitations, that can be 
summarized in the following Table 2 21,42. 
  
 ASO-based therapy Gene therapy Small molecules 
Administration 
Intratecal 
• Higher cost 
• Might require multiple 
injections periodically 
• Some patients that are 
diagnosed late in life might not 
be able to receive this treatment. 
Intravenous 
• More comfortable 
• Vector can access both the 
peripheral tissues and the CNS. 
• If multiple doses are required, 
it makes it simpler. 
Oral 
• Requires no technical 
knowledge to administer 
• They can cross the brain 
blood barrier. 
Drug distribution Does not reach peripheral tissues. 
Would have to be 
administered very early in life 
to be able to reach the CNS. 
The action mechanism is 
not well known yet, might 
have off-target effects. 
SMN level rescue Might be incomplete in peripheral tissues. 
Might be incomplete if 
immunogenicity is developed 
after multiple doses. 
 
Table 2. Comparative table between the three types of therapy discussed in this work. 
 
4.4. Future of SMA therapy 
Considering the fact that Nusinersen has already been approved by the FDA, it becomes impossible 
to think about the future of SMA therapy without talking about synergy. As it would not be moral to deny 
patients an existing treatment, new drugs will have to be able to work alongside with Nusinersen, 
complement its effects, and combinatorial models will have to be used for clinical trials 42. Not only that, 
but the possibility that rescuing the phenotype only in αMNs might not be sufficient to fully cure the 
muscular atrophy, suggests there is still a lot to learn about SMN’s role in the peripheral tissues. 
Furthermore, it is still unclear what other symptoms patients currently being treated with Nusinersen 
might develop as they grow up, and whether the lack of SMN during development will have lasting effects, 
even after the administration of the drug. Other patients, such as those with milder forms of the disease 
that do not get diagnosed until later in life, might also not respond as well to Nusinersen as type I SMA 
patients have. As these new symptoms are being reported, complementary treatments and further support 
of care in hospitals for the new clinical challenges they will bring along, will be needed 42,44. Similarly, 
establishing a therapeutic time window would allow to minimize these developmental issues. Through post-
natal screening, it would be possible to initiate the treatment during the pre-symptomatic stage, thus 
minimizing the amount of neurodegeneration that takes place. While this window is better known for type 
I SMA – most of the neurodegeneration takes place during the first 6 months of life – such is not the case 




HYPOTHESIS AND OBJETIVES 
Therapies aimed to increase the levels of defective SMN protein, such as the antisense 
oligonucleotide (ASO) Nusinersen (SpinrazaTM), have considerably changed the landscape of SMA clinical 
management. Assays in mouse models of severe SMA have shown that this ASO significantly extends 
lifespan and improves motor behavior. These findings have encouraged a rapid transition of pre-clinical to 
clinical trials, in which administration of this agent has resulted in remarkable improvements in SMA type 
I patients. Despite the promising results with nusinersen, the cellular and molecular mechanisms underlying 
its pharmacological action are scarcely known. This point is important in order to trace complementary 
therapies targeting peripheral tissues, particularly skeletal myofibers, which persist disturbed despite 
Nusinersen treatment. In this vein, there is growing evidence that, besides MNs, numerous peripheral 
organs are severely affected in SMA pathology. Consequently, increasing SMN levels exclusively in MNs, 
as achieved with the currently routes of this drug administration, appears not to be enough for the treatment 
to be effective. 
In this context, our work is aimed to examine the impact of the ICV administration of Nusinersen 
at neonatal period on pathological changes provoked by the SMN deficiency in αMNs, particularly in 
nuclear pre-mRNA processing machinery and mature mRNA export to cytoplasm, as well as motor 
performances, using the SMNΔ7 mouse model of SMA. 
The main objectives are:  
1. To test to which extent motor function can be improved or reverted with ICV administration of 
Nusinersen in neonatal mice. 
2. To identify the cellular bases of Nusinersen effects at the motor unit level. Particularly: 
a. The degree of recovery of αMNs  
b. The expression of two key genes for αMNs homeostasis such as Chodl and ChAT 
c. The behavior of CBs in αMNs, which are involved in snRNP biogenesis 
d. The subcellular distribution of poly(A) RNAs in the nucleus and cytoplasm of αMNs, 
with a special emphasis on the recovery of mRNA export and consequent decrease of 
PARGs. 
e. The organization of protein synthesis machinery, particularly of Nissl bodies. 
f.  The size and organization of skeletal muscle fibers, including the oxidative pattern 
estimated with the SDH assay. 
 We consider that the new concepts emerging from this work will facilitate a better understanding of 
the complexity of cellular mechanisms of the disease, and also increase our knowledge on the benefits and 






MATERIALS AND METHODS 
1. Animal procedures 
1.1. The SMN∆7 mouse model 
The model used for the experiments is the SMN∆7 transgenic mice, an SMA type I mice model 
(Jackson Laboratory stock number 005025). In this model, the mouse Smn gene was disrupted and, 
additionally, two copies of the human transgene SMN2, along with the cDNA coding for the truncated 
protein SMN∆7 (Smn-/-; SMN2+/+; SMN∆7+/+) were introduced into the mouse genome 47. This mouse, 
created by the Brughes Lab in 2005, show an homozygous recessive phenotype, in which a loss of muscle 
mass can be seen from birth, and have a two-week life expectancy 47. 
To obtain the SMN∆7 animals, heterozygous knockouts (Smn+/-; SMN2+/+; SMN∆7+/+) were 
crossed. As controls, Smn+/+; SMN2+/+; SMN∆7+/+ (WT) mice were used. On P0, a small sample from the 
tail was clipped to extract the gDNA and the mice were genotyped by PCR.  
1.2. PCR genotyping 
To confirm each mouse’s genotype by PCR, a tip of the mouse tail is cut and gDNA extracted using 
the Phire Tissue Direct PCR Master Mix kit (Thermo). PCR (polymerase chain reaction) allows the 
amplification of specific genes, which can then be run through horizontal electrophoresis to compare the 
size of the amplified DNA with a marker of known standards. To detect the alleles Smn+ and Smn- we 
designed PCR primers so the two products have different lengths and are easy to differentiate with PCR 
(Figure 11). Their specific sequence primers were: Smn+ and Smn- forward 5´-CTCCGGGATATTGGGA 
TTG-3´; Smn+ reverse 5´-TTTCTTCTGGCTGTGCCTTT-3´ and Smn- reverse 5´-GG 
TAACGCCAGGGTTTTCC-3´. Since Smn+ and Smn- allele amplicons show different sizes (800 bp for 
Smn+ and 500 for Smn-), it is possible to directly determine the genotype of the mouse them in the agarose 
gel.  
For the whole genotyping procedure, we used the Thermo Scientific, Phire Tissue Direct PCR Master 
Mix kit. The gDNA is extracted by incubating the tails tips with the extraction buffer and centrifugation, 
according to the manufacturer’s instructions. The supernatant is collected, and the primers are added to it, 
as well as the PCR Master Mix. For amplification we used a termocycler during 30 amplification cycles, and 
then the samples are analyzed in an agarose gel (1%) with UV transillumination.  
 
Figure 11. Representative 
example of a SMN∆7 genotyping 
PCR. Bands for the Smn+ allele, 
appear at 800bp and for Smn- allele 
at 500 bp. 
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1.3. Nusinersen intracerebroventricular administration  
Intrathecal delivery methods enable the administration of soluble therapeutics directly into the central 
nervous system (CNS), in order to bypass the blood-brain barrier (BBB), and are commonly used to treat 
a variety of diseases in pediatric and adult patients. As an intrathecal delivery method, the 
intracerebroventricular (ICV) route of administration introduces the therapeutic agent into the cerebral 
ventricles. In our model, we delivered a single dose of 6,5 mg/kg of the ASO Nusinersen to both, WT and 
SMN∆7 mice at P0-1, via 4µl ICV injection of SpinrazaTM (Biogen). As control group, we administered an 
equal volume (4µl) of 0,9% saline solution. All mice were monitored daily and sacrificed at P12. 
To do the ICV delivery procedure, mice are cryo-anesthetized for a couple of minutes on an ice 
surface with tissues to avoid direct contact of the skin and the ice.  Holding the mouse by the skin of its 
neck against a light source, we located the sagittal suture in the skull. The needle should be inserted 
approximately 0,25 mm lateral to the sagittal suture, and 0,5 – 0,75 mm rostral to the neonatal coronary 
suture (Figure 12). Using a 1ml Hamilton syringe loaded with 4µl of Nusinersen (5mg/12ml) we introduce 
the needle to only penetrate the skull 2 mm. Then, slowly inject the solution and monitor for ruptured 
vessels or facial swelling. Wait 15 seconds before removing the needle, and let the mice recover for 5-10 
minutes in a warmed container or until they are responsive 48. 
1.4. Motor righting reflex test 
The motor righting reflex test was first described by Altman and Sudarsan in 1975 49, and ever since 
has been used as a measure of rats and mice motor coordination, as there are multiple movements involved 
in turning the body 180º 49.  
The test consists in placing the mouse on its back and measuring the time that it takes for the mouse 
to right itself on the surface. As this is a reflex and requires no learning, it’s ideal for neonatal testing. In 
this work, the test was conducted according to the protocol of Feather-Schussler and Ferguson 50. It consists 
of holding the mouse on its back against a surface for five seconds, and then releasing it. Then, the time is 
measured until it returns to prone position, up to 30 sec for each test. The motor righting reflex test was 
performed thrice per stage, at P0, P3, P6, P9 and P12 in control WT (0,9% NaCl), vehicle-treated SMN∆7 
mice (0,9% NaCl) or Nusinersen-treated SMN∆7 mice (6,5 mg/kg).  
 
Figure 12. View of the head of a 
neonatal mouse against a light source. 
The transverse sinus can be seen 
through the skin, helping determine 
where the injection will be made. Taken 
from Glascock et al 2011 48.  
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1.5. Tissue extraction 
To extract the spinal cord, a very soft tissue, the entire thoracic cage is extracted. The mice are 
sacrificed and then the torso is cut off under the forelimbs and above the hindlimbs. The skin is removed, 
and then the ribcage is dissected and fixed by immersion in 3,7% freshly prepared paraformaldehyde (PFA) 
(Figure 13A-C). After a few hours, when the tissue has already hardened slightly, the bone is cut to reveal 
the spinal cord, which is then extracted with forceps ) (Figure 13D-E). The lumbar section is then located 
and cut from it.  
As for the muscle samples, from the hindlimbs, the tibialis anterior (TA) was obtained (Figure 14). 
The skin is removed from a sacrificed animal, and the limb is secured with the help of pins. The first tendon 
in the ankle is stretched with forceps and cut with a blade, pulling the muscle away from the bone until the 
knee is reached. Once the muscle is completely separated, it is pinned to cork and immersing it in ice-cold 
relaxing buffer (100 mM NaCl, 2 mM KCl, 2 mM MgCl2, 6 mM K3PO4, 1 mM EGTA, and 0.1% glucose; 
pH 7.0), then kept at 4ºC until fixed in 3.7% PFA. The fragments are cryoprotected in 15% and 30% 
sucrose in PBS (phosphate saline buffer: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM 
KH2PO4; pH 7.4) until they sink to the bottom of the jar. Then, they are embedded in Tissue-Tek OCT 
Compound (Sakura FineTek USA) and frozen on a chilled metal block in dry ice. Afterwards, cryosections 
are obtained (8 µm-thick) and mounted on SuperFrost slides that can be stored at -80ºC until use.  
 
 
Figure 14. Extraction of TA muscle from 
a mouse’s hindlimb. Image from Wang, 2017. 74  
Figure 13. A-C. Extraction of the toracic cage and spine of a mouse. Images taken from Eldeiry, 2017 72. D-
E. Extraction of the spinal cord from a ribcage. Images taken from Lin, 2018. 73 
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2. Cell Biology procedures 
2.1. Succinate dehydrogenase (SDH) assay 
The SDH is an enzyme that participates in the citric acid cycle, and in the electron transmission chain, 
both processes taking place in the mitochondria. For this reason, it is used as a marker for mitochondria 
and high levels of SDH in muscle indicate the oxidative activity of the fibers. When the SDH in the tissue 
comes in contact with succinic acid from the buffer, an electron transfer occurs and causes a color change 
that can be measured. As explained above, the content of mitochondria and the oxidative activity of each 
fiber determines its type. Type I myofibers have the highest SDH response, while type IIb have the least, 
with type IIa in between these two. This test was performed in order to understand the effect of the 
Nusinersen on the muscle fiber phenotype. 
To do so, cryosections of the non-fixed TA muscle (8 µm) were incubated in a SDH reaction mixture 
(1.5 mM nitroblue tetrazolium, 5 mM EDTA, 48 mM succinic acid, 0.75 mM sodium azide, 30 mM 
methylphenylmethyl sulfate, and phosphate buffered pH 7), whereas the controls were incubated in succinic 
acid-free medium. Afterwards, samples were air-dried and mounted. They were observed under a 
fluorescence microscope (Zeiss, Axioscop Plus) under an oil objective of either 40x or 63x. Once images 
were captured, a morphometric analysis was performed of at least 100 myofibers per animal (n=3 in each 
group). Fiber diameter was measured on randomly collected images (40x) using the ImageJ software 
(National Institutes of Health). 
2.2. Immunofluorescence and confocal microscopy 
Four mice per group were fixed by perfusion with 3.7% freshly-prepared PFA in PBS under deep 
anesthesia with pentobarbital (50 mg/kg). Once fully asleep, the mice were pinned to a board and an 
incision on the chest area was made to access the heart. A syringe with the PFA was inserted on the left 
ventricle, and the right atrium is perforated so that the blood may exit. After all the PFA has entered the 
body and the fluid leaving through the atrium incision is no longer blood, the perfusion is finished. The 
animals were then cut off under the forelimbs and just above the hindlimbs, leaving only the trunk. From 
the trunk, the skin is removed to be able to pinch the column with our fingers, exposing the spinal cord as 
a small white dot. Once located, saline solution is introduced with a syringe to push the spinal cord through 
the opposite end into a Petri dish. The tissue is post-fixed for 6 hours and washed in PBS. 
After post-fixation, the samples were cut into 160 µm-thick transverse sections with a vibratome, and 
dissected into small fragments from the anterior horn. These were then transferred to a drop of PBS on a 
positively charged slide (Superfrost Plus, Thermo Scientific, Germany). After that, a slide cover is placed 
on top and the sample is tapped gently in a perpendicular angle, with a histologic needle. After a few 
seconds, the neurons will have dissociated. The slides are placed face down on metal plaques, inside a 
container with dry ice. To prepare them further for immunofluorescence, the slide cover is removed, and 
samples are treated with glycine to eliminate the aldehyde residues left by fixation, and then permeabilized 
with PBS-Triton-X-100 0,5% for 45 minutes at room temperature, and washed with PBS-Tween-20 0,05%. 
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After that the area around the sample is delimited with a diamond pen, before adding the primary antibody 
(7 µl), diluted in PBS with 1% BSA. The samples are kept in a dark and humid chamber at room temperature 
for three hours, or overnight at 4ºC 51,52. 
The primary antibodies were: mouse monoclonal anti-SMN (diluted 1:100, catalog no. 610646, BD 
Transduction Laboratories, USA); mouse monoclonal anti-TMG-cap (NA02A, Oncogene, USA); mouse 
monoclonal anti-fibrillarin (diluted 1:100, catalog no. ab4566, Abcam, USA); rabbit polyclonal anti-coilin 
(1:500, 204.10, Prof. A. Lamond, Dundee, UK); and goat polyclonal anti-choline acetyltransferase (ChAT) 
(1:200, AB144P, Millipore, MA, USA). As for the secondary antibodies, they were conjugated with FITC, 
Texas Red or Cy3, or Cy5 (diluted 1:75, Jackson, USA). Some samples were counterstained with propidium 
iodide (PI) or Phalloidin-FITC, and samples were mounted with ProLong Anti-Fading Medium 
(Invitrogen). 
Using a laser scanning confocal microscope (LSM510, Zeiss, Germany – 63x oil 1.4 NA objective), 
the samples were excited sequentially at 488 nm and 543 nm to obtain images, thus avoiding signal overlap. 
The intensity of the signal was generated using confocal images of double immunolabeled samples and 
processing the images with Adobe Photoshop CC6 software. 
2.3. In situ hybridization of poly(A)RNAs 
Fluorescence in situ hybridization (FISH) was performed on αMN dissociates to detect the spatial 
distribution of polyA RNA, using an oligonucleotide probe conjugated with biotin. The preparations are 
permeabilized with TBS-E-SDS for 15 min at 37ºC so that the probe could reach the RNA. Then, they are 
washed thrice in 6x SSPE-0,1% Tween 20 for 15 min, and incubated with the tRNA probe for 3 hours at 
42ºC in a humidified chamber. After hybridization, the samples are washed in 6xSSC, and then in 4xSSC-
0,1% Tween 20 (15 min each, room temperature). All samples were mounted with Vectashield (Vector, 
USA) and the signal was detected with FITC-avidin. 
 
3. Molecular Biology procedures 
3.1. qRT-PCR for relative gene expression analysis 
Quantitative reverse transcription polymerase chain reaction, or qRT-PCR, combines the PCR 
amplification of a specific gene with the ability to measure how long it takes for that amplification to reach 
a peak signal. To do this, the nucleotides that will create the new DNA strands carry with them a 
fluorochrome that becomes visible when it joins the complementary chain, allowing a real time observation 
of the chain reaction speed, and the concentration of new DNA. Because it is performed starting from a 
mRNA sample, it is then converted in DNA (complementary DNA, cDNA) via reverse transcription with 
a High Capacity cDNA Reverse Transcription Kit (Life Technologies).  
mRNA was extracted from the spinal cord of four mice per group, isolated with TRIzol (Invitrogen, 
Carlsbad) following the manufacturer’s instructions, and purified with the RNeasy kit (Qiagen, Hilden, 
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Germany). The expression of Gapdh, ChAT and Chodl was determined using gene-specific SYBR Green-
based primers (Takara). The fluorescence is measured during the 40 cycles of PCR and the threshold cycle 
(Ct) is established on the cycle that the fluorescence is first captured, once the collective signal from all the 
DNA being amplified is enough to trigger the machine. The results were normalized to GAPDH, and the 
comparison between relative gene expression of ChAT and Chodl was calculated following the 2-(∆∆Ct) 
equation 53. The primers for pre-mRNA of ChAT were 5´-CTTGGGGCCAGTCTGATAGC-3′ and 5′-
GGA CACATGGCTAGAAGGGG-3′, for the pre-mRNA of Chodl 5′-GCTGTTGTCTCCCGCATCTT-
3′ and 5′-AAGTGGAAGCGTTTGGGATT-3′, and for the pre-mRNA of Gapdh 5’- AGGTCGGTG 
TGAACGGATTTG-3’ and 5’- TGTAGACCATGTAGTTGAGGTCA-3’. 
3.2. SDS-PAGE and immunoblotting 
Samples of the spinal cords and muscle were obtained from not perfused animals (n=3 in WT and 
SMN∆7 groups; n=4 in Nusinersen-treated SMN∆7 group). They were lysed in a lysing buffer at 4ºC (50 
mM Tris (pH 8), 150 mM NaCl, 2% Nonidet NP-40, 1 mM MgCl2, 1 mM dithiothreitol, and 10% glycerol 
and supplemented with EDTA-free complete protease inhibitor cocktail and PhosphoSTOP (Roche)), then 
sonicated to break up the tissue completely with short pulses of five seconds, then placed in ice. Then they 
were cleared by centrifugation at 14000 rpm for 10 min at 4ºC, then diluted in an equivalent volume of 2x 
(Laemmli loading buffer).  
To separate the proteins, commercial gels (4-20% NuPage TG SDS-PAGE gels, Invitrogen) were 
used. Afterwards, the proteins get transferred to a nitrocellulose membrane using standard procedures, 
which is blocked with milk protein. Mouse monoclonal anti-SMN (1:5000) and rabbit polyclonal anti-lamin 
A/C (1:1000) are used, and after adding the secondary anti-mouse and anti-rabbit antibodies, the protein 
bands are visualized with an Odyssey™ Infrared-Imaging System (Li-Cor Biosciences). For quantitative 
analysis of the blots, ImageJ software was used (U.S. National Institutes of Health, Bethesda, Maryland, 
USA, http://imagej.nih.gov.ij). 
4. Statistical analysis 
The data in this work has been expressed as mean ± SD and has been analyzed using GraphPad 
Prism 7 software and PASW Statistics 22 (SPSS, Inc.) packages. Four mice per group were examined, when 
quantification analysis was performed to evaluate the mean number of CBs per αMN and the proportion 
of PARGs-containing αMNs in at least 100 αMNs per group. This was done by examining the images 
obtained from neuronal dissociates after observing the nuclei under a 40x objective throughout various 
focal planes. The statistical analysis was assessed by one-way ANOVA or mixed-design two-way ANOVA 
(Split-Plot ANOVA), followed by the Bonferroni post hoc test (SPSS) or Student’s t test (GraphPad) as 





The severe forms of SMA, type 0 and I, are associated with early mortality in most cases and severe 
disability in survivors. As mentioned, SMA is characterized by progressive muscle weakness caused by the 
loss of spinal cord αMNs. Fundamental activities using muscles, such as walking, sitting up, controlling 
head movement, breathing, and swallowing is affected in SMA. Movement progressively becomes slower 
and its ability to the voluntary control may be lost completely in the later stages of the disease. Currently, 
there is no cure for SMA, but there are encouraging treatments as novel genetic therapies based on the use 
of the antisense oligonucleotides (ASOs). 
The ASO Nusinersen (now available as SpinrazaTM from BIOGEN), promotes production of full-
length SMN protein targeting the SMN2 gene, and was recently approved by the European Medicines 
Agency and the US Food and Drug Administration. Clinical studies in type I SMA patients, demonstrate 
that Nusinersen is safe and well tolerated and no drug-related adverse events are observed, doubling SMN 
levels after a single dose, prolonging survival of patients and allowing motor milestone acquisition 6. Patients 
with type II SMA also show progress on different motor scales after Nusinersen treatment 54. Nusinersen 
thus represents the first efficacious marked approved drug in type I and type II SMA 55. 
In 2018, our laboratory signed an MTA contract with the pharmaceutical company BIOGEN to 
analyze if the restoration of SMN expression with the administration of Nusinersen reverts the severe 
dysfunction of nuclear RNA metabolism previously reported by our group in αMNs of the SMN∆7 mice 
56,57. For that purpose, an effective Nusinersen treatment protocol, based on the intracerebroventricular 
(ICV) injection of ASOs in neonatal (P0-1) SMN∆7 mice, was adopted 58. The results herein presented 
show the neuroprotective effects of Nusinersen based on the restoration of neuronal RNA homeostasis as 
well as the improvement on motor function 1. 
1. Treatment with ASO-nusinersen robustly recovers the growth curve, 
enhances motor function, and dramatically reduces αMN loss. 
Previous results from our laboratory had shown that, in the mouse model of type I SMA, the SMN∆7 
mouse, SMN deficiency produces, as one of the earliest signs of αMN degeneration, the functional 
depletion of CBs and the loss of CB-nucleolus interactions. This neuronal response induces a 
progressive nucleolar dysfunction in ribosome biogenesis with reorganization and loss of nucleolar 
transcription units, segregation of dense fibrillar and granular components, retention of SUMO-conjugated 
proteins in intranucleolar bodies and a reactive, compensatory, up-regulation of both mature 18S rRNA 
and genes encoding key nucleolar proteins, such as the upstream binding factor (UBF), fibrillarin, nucleolin 
and nucleophosmin 56. These CB and nucleolar alterations might participate in the dysfunction of rRNA 
synthesis/processing reported in SMA by several groups, including ours. Consequently, we support that 
SMA must be included in the emerging group of pathologies known as "RNAopathies" 39. 
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Later, our group showed that αMN-SMN∆7, exhibit the abnormal nuclear accumulation of 
polyadenylated RNAs in specific granules, known as PARGs. These were also enriched in the splicing 
regulator Sam68. Despite the absence the other RNA-binding proteins in these PARGs, the abnormal 
nuclear accumulation of polyadenylated mRNAs suggests that they cannot be exported to the cytoplasm 
for translation. Furthermore, these effects were accompanied by changes in the alternative splicing of the 
Sam68-dependent Bcl-x and Nrnx1 genes, as well as changes in the relative accumulation of the intron-
containing Chat, Chodl, Myh9 and Myh14 mRNAs, which are all important for MN functions 57. 
Now, in the work herein presented, our first aim was to analyze the global effects of the treatment 
with the ASO-Nusinersen in neonatal SMN∆7 mice (P0-1). Although low levels of SMN are systemic, the 
primary affected cell population is αMNs. Since ASOs do not cross the blood–brain barrier (BBB) when 
administered systemically 59, to reach the αMNs we decided to administer Nusinersen via ICV (Figure 
15A), according to the protocol described by Glascock et al 2011 48. The experimental groups were: (i) WT 
treated with 4µl of Nusinersen (dose 6,5mg/Kg), (ii) WT treated with 4µl of 0.9% saline solution (hereafter, 
WT), (iii) SMN∆7 treated with Nusinersen (dose 6,5mg/Kg), and (iv) SMN∆7 treated with 4µl of 0.9% 
saline solution (hereafter, SMN∆7). All mice recovered shortly after injection without any detrimental side 
effects.  
First, we wanted to evaluate the efficiency of the treatment with Nusinersen on the restoration of 
SMN protein levels in both the CNS (SMN levels should be back to normal if ICV delivery was performed 
successfully) and in a non-CNS tissue as the skeletal muscle (SMN levels should be low). To test this, 
western blot analyses were performed in tissue lysates collected at P12 from the four study groups (Figure 
15B). We found that SMN levels in Nusinersen-treated SMNΔ7 spinal cords samples were 2.5 times higher 
than in the vehicle-treated SMNΔ7 samples. When compared to the WT groups, the SMN level reached 
approximately 70% of their level (Figure 15B, left panel). Furthermore, skeletal muscle samples from 
Nusinersen-treated SMN∆7 mice confirmed that Nusinersen does not reach organs outside the CNS, since 
SMN protein levels were not increased relative to untreated SMNΔ7 mice (Figure 15B, right panel). 
 
Figure 15. (A) Illustration of the intrathecal injection point of the ASO-nusinersen (Spinraza™). (B) Western 
blot analysis of SMN protein levels in whole spinal cord and skeletal muscle lysates at P12. In the SMNΔ7 mouse 
SMN levels are low in both spinal cord and muscle, and it recovers when Nusinersen is injected, but only in the spinal 
cord, not in muscle. The SMN bands were normalized to laminA, a protein present in the nuclear lamina, associated 
to the nuclear envelope. The images were analyzed using ImageJ. 
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Once verified that Nusinersen was efficiently being delivery to the CNS through the ICV injection, 
and that SMN protein levels were restored near to WT levels in the Nusinersen-treated SMN∆7 spinal cord 
samples, we decided to study the global impact of αMN-specific SMN restoration in the whole body 
growth, net weight gain and motor function of SMN∆7 mice treated with one single dose of ASOs at P0-
1. The visual observation of SMN∆7 mice showed that they are already born lacking mobility and muscle 
mass. As they grow, they seem to struggle to grow in length and gain weight at the same rate as WT 
littermates (Figure 16A). At the clinical phase (P6 to P12), symptoms appear more evident and progress 
until death occurs between P12 and P14. However, when we compared the Nusinersen-SMN∆7 mice to 
their WT littermates were almost indistinguishable (Figure 16B), and although they had ambulation 
capacity a moderate hindlimb paresis was noticeable in these animals when compared to WT mice. 
Next, to compare the body growth rate, vehicle-treated WT and SMN∆7 Fig. 2RB 7 mice, as well as 
Nusinersen-treated SMN∆7, were weighted at P0, P3, P6, P9 and P12. While the Nusinersen-treated WT 
group (data not included in the graph) did not show any significant body weight differences from the 
vehicle-treated WT mice, it was clear that the treatment on SMN∆7 mice had a positive impact. Their 
growth in weight was comparable to that of the WT group after P6, and about double the growth of vehicle-
treated SMN∆7 mice at P12 (Figure 16C). Furthermore, we also analyzed motor functions of the 
Nusinersen-SMN∆7 mice, using the righting reflex test. In this test, the mouse is placed on its back and the 
time it needs to right itself is measured up to 30 seconds. This evaluates the overall muscle strength and 
motor coordination of the mice. In the case of untreated SMN∆7 mice, they never acquire the righting 
Figure 16. (A) Comparison between a WT and a SMNΔ7 mouse at P12. (B) Comparison between a WT and 
a Nusinersen-treated SMNΔ7 mouse at P12. (C) Graph comparison of body weight (mean ± SD) between WT, 
SMNΔ7 and nusinersen-treated SMNΔ7 mice from P0 to P12 (n = 8 mice per group). The Nusinersen-treated SMNΔ7 
mice (yellow) reach weights comparable to the WT group (green), unlike the untreated SMNΔ7 group (red). #p < 
0.01, ###p < 0.0001: WT vs. SMN∆7; ***p < 0.0001: vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7. (D) 
Graph showing the time needed to acquire the righting motor reflex and the time needed to complete the test (mean 
± SD). The Nusinersen-treated SMNΔ7 mice (yellow) acquire the reflex a little later and take longer to complete the 
test than the WT group (green), but the response is much improved from the untreated SMNΔ7 mice (red), who never 
acquire the reflex to begin with. (n = 8 mice per group). ###p < 0.0001: WT vs. SMN∆7; ***p < 0.0001: vehicle-
treated SMN∆7 vs. Nusinersen-treated SMN∆7. In C,D, data were analyzed by a one-way ANOVA, followed by the 
Bonferroni post hoc test using SPSS. 
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reflex during the period studied (P0-P12), while both Nusinersen-treated SMN∆7 and WT mice are capable 
of righting themselves from P3 onward. However, Nusinersen-treated SMN∆7 mice required more time to 
do so (Figure 16D). It is noteworthy, that although SMA severely impairs mobility due to muscular atrophy, 
which was observed in the vehicle-SMN∆7 group, Nusinersen-treated SMN∆7 mice only exhibit moderate 
hindlimb atrophy, and they are able to walk on their own.  
Western blot analysis of the tibialis anterior (TA) muscle clearly indicated that Nusinersen does not 
cross the BBB in neonatal mice, leaving the peripheral organs unable to produce full length SMN protein. 
Therefore, seems sensible to deduce that the clinical effects of the ASO treatment are primarily due to the 
increased expression of SMN in the spinal cord. To examine SMN expression and distribution specifically 
in the αMNs, we performed SMN immunolabeling experiments using transversal cryosections from whole 
spinal cords at the L5 level. Thus, the SMN staining pattern in Nusinersen-treated SMNΔ7 αMNs was 
similar to the one in WT neurons, that included a diffuse signal in the cytoplasm, and accumulation of SMN 
signal in nuclear CBs (Figure 17A and C). On the contrary, vehicle-treated SMNΔ7 αMNs exhibited a 
notably weak cytoplasmic signal of SMN, and CBs were rarely observed (Figure 17B).  
Figure 17. (A–C) Immunodetection of SMN, where the treatment with nusinersen rescues the typical SMN 
staining pattern (A) in nusinersen-treated SMNΔ7 cells (C) – diffuse cytoplasmatic signal and concentrated in CBs, 
while the untreated SMNΔ7 neurons (B) show a much weaker signal in the cytoplasm and CB depletion. (D–F) 
Immunodetection of ChAT in the anterior horn of spinal cord allows to count the number of αMNs and compare 
the average between groups. The Nusinersen-treated SMNΔ7 cells (F) recover in number to be comparable with the 
WT animals (D), while the untreated animal has less αMNs (E). Scale bars: 10 µm (A–C), 30 µm (D–F). 
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In terms of αMN survival, immunostaining for ChAT, a marker of αMNs, was performed, followed 
by quantitative analysis of the average percentage of ChAT-positive MNs at each anterior horn on 8-µm 
thick cryosections (Figure 17D-F). In Nusinersen-treated anterior horns, the αMN population is preserved 
when compared to WT, with no significant differences in the mean number of αMNs per section, while in 
vehicle-treated SMNΔ7 mice had a clear depletion of αMNs per anterior horn, as seen in Figure 17D-F. 
Once observed that Nusinersen treatment preserves αMNs and presumably the formation and 
maintenance of the NMJ, we investigated whether it can also prevent the neurogenic myopathy that the 
SMN∆7 mice develop. First, to determine the existence of muscular atrophy, we analyzed the myofiber size 
distribution in cross-cryosections of the TA muscles stained with phalloidin-FITC, a marker of thin actin 
filaments (Figure 18A-C). Despite the reduced level of SMN protein in SMNΔ7 mice muscles (Figure 
15B, right panel), non-significant differences in myofiber diameter were found between saline-WT mice 
and Nusinersen-treated SMN∆7 mice at the symptomatic P12 stage (Figure 18G). It is noteworthy the 
significant reduction of the myofiber diameter detected in vehicle-SMN∆7 mice compared with WT and 
Nusinersen-SMN∆7 mice (Figure 18G).  
Figure 18. (A–C) Phalloidin-FITC staining of transverse cryosections of TA muscle at P12, showing 
distribution of myofiber in WT muscle (A), and how the Nusinersen-treated mice recovered the myofiber normal 
diameter (C) vs the untreated animals who showed atrophied fibers with smaller diameters (B). (D–F) SDH 
histochemical staining of WT (D), SMN∆7 (E) and nusinersen-treated SMN∆7 TA muscle (F) at P12. The different 
myofiber types are labeled in the image (1, 2A, 2X). While in untreated SMN∆7 mice the main phenotype is the 
smaller type 1 myofibers, the Nusinersen-treated SMN∆7 mice recover the same phenotype as the WT animals. 
(G) Quantitative analysis of the mean myofiber diameter at P12 (mean ± SD). (H) Quantitative analysis myofiber 
type on transverse TA muscle based on SDH staining. Scale bars: 15 µm (A-F). 
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To further understand the myofiber response to Nusinersen treatment, we performed the succinic 
dehydrogenase (SDH) histochemical assay, as a marker of the mitochondrial oxidative activity. SDH 
histochemistry on cross-cryosections of the TA muscle revealed that both WT and Nusinersen-treated 
SMN∆7 myofibers exhibited a staining checkboard pattern of a mixed muscle with a similar myofiber size 
distribution (Figure 18 D and F). Moreover, there was a comparable proportion of myofibers whose SDH 
oxidative activity corresponded to either type 1 or type 2A and 2X (Figure 18H). In contrast, vehicle-
treated SMN∆7 myofibers were clearly atrophic with reduced diameter, as demonstrated in our previous 
analysis (Figure 18G), and an oxidative intensity of stain predominantly corresponding to type 1 (Figure 
18E, H). 
 
2. Nusinersen treatment prevents disruption and loss of canonical CBs in 
αMN of the SMA model. 
Once we have confirmed that Nusinersen treatment normalizes SMN protein levels in the spinal 
cord and preserves αMN population, we next wanted to investigate the status in terms of formation and 
functionality of canonical CBs in the Nusinersen-treated SMN∆7 αMNs. Canonically, CBs are spherical 
structures of around 0,5 µm of diameter, whose main component is coilin. Since these nuclear organelles 
are involved in pre-mRNA processing, the number and size of CBs depend on transcription rate of the cell, 
changing to accommodate the requirements for pre-mRNA splicing. SMN plays an important role in 
formation of CBs, and previous studies have shown that upon SMN protein depletion, canonical CBs 
disappear, followed by relocalization of coilin as perinucleolar caps and/or within the nucleolus 37,60. Thus, 
CB disruption can be considered an early nuclear sign of αMN degeneration in SMA. 
First, we performed double immunolabeling experiments to visualize coilin, the structural protein 
and molecular marker of CBs, and SMN. The SMN distribution, as mentioned above, was diffuse in the 
cytoplasm and concentrated in nuclear bodies. These were identified as canonical CBs because they 
concentrated both SMN and coilin. Moreover, CBs showed a preferential association with the nucleolus in 
both WT and Nusinersen-treated SMN∆7 αMNs (Figure 19A and C). This was, however, not the case in 
the vehicle-SMN∆7 αMNs, where coilin-positive aggregates were depleted of SMN an coilin relocalized 
forming perinucleolar caps where SMN was scarcely detected (Figure 19B). Next, to determine the precise 
effect of Nusinersen treatment on CB formation, a quantitative analysis of the mean number of CB per 
nucleus was performed. To do this, neuronal dissociates were coimmunostained for coilin and SMN. No 
significative differences were found between WT and Nusinersen-treated SMN∆7 αMNs at P12, however, 
in vehicle-treated SMN∆7 αMNs at P12, during the clinical phase, the mean number of CB per nucleus 




To confirm that Nusinersen induces the concentration of SMN in CBs, we performed a detailed co-
localization analysis from the confocal fluorescent signals from both SMN (green) and coilin (red). Thus, 
as shown in Figure 20A, C, the profile of fluorescence intensity signals across a line that passed through 
two CBs from a WT or a Nusinersen-treated SMN∆7 αMN confirmed the co-localization of coilin and 
SMN in canonical CBs.  In contrast, in vehicle-treated SMN∆7 αMNs, the linear profile shows the absence 
of fluorescence SMN signal from perinucleolar coilin-positive caps (Figure 20B). 
 
Figure 19. (A–C) Confocal images of dissociated αMNs from WT (A), SMN∆7 (B) and nusinersen- treated 
SMN∆7 mice (C) double immunolabeled for coilin (red) and SMN (green). In both WT and Nusinersen-treated 
SMN∆7 αMNs there are canonical CBs, in which coilin and SMN colocalize. However, in untreated SMN∆7 αMNs 
the coilin forms perinucleolar caps, and the SMN signal is very weak in comparison to the other two. Scale bars: 20 
µm (A–C). 
Figure 20. Confocal images of dissociated αMNs from WT (A), SMN∆7 (B) and Nusinersen-treated SMN∆7 
mice (C) double immunolabeled for coilin (red) and SMN (green). Upon performing a colocalization analysis, the 
profile of fluorescence signal across two CBs shows whether colocalization is precise in canonical CBs. In WT and 
Nusinersen-treated SMN∆7 αMNs, the profiles show the fluorescence has an intensity peak in both signals in the 
same location (A, C). However, in untreated SMN∆7 mice there is no SMN signal (B). The intensity of the signal was 
analyzed with ImageJ software. 
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To determine whether the CBs formed in Nusinersen-treated SMN∆7 αMNs were functional in 
spliceosomal snRNP maturation or snoRNPs biogenesis, double immunolabeling for coilin with TMG-cap 
or fibrillarin was performed. TMG-cap is a marker for the 5’ end of snRNAs and is used as a spliceosomal 
snRNPs marker. Fibrillarin is a protein component of nucleolar snoRNPs that is concentrated in the fibrillar 
centers of the nucleolus and canonical CBs. Both signals, each corresponding to molecular markers of 
snRNP and snoRNPs, respectively, colocalized with coilin in the CBs of WT and Nusinersen-treated 
SMN∆7 αMNs (Figure 21A-F). However, this was not the case for perinucleolar caps of vehicle-treated 
SMN∆7 αMNs, indicating these coilin-positive structures cannot participate in the biogenesis of both, 
snRNPs nor snoRNPs. These observations were also confirmed by the profiling of the confocal 
fluorescence signals across a line (red for coilin and green for TMG-cap or Fibrillarin) shown in the Figure 
21. As a final note, Gems, coilin-negative and SMN-positive nuclear bodies, were absent in all experimental 
groups studied. 
Figure 21. (A–F) Confocal images of dissociated αMNs from WT (A, D), SMN∆7 (B, E) and Nusinersen-
treated SMN∆7 mice (C,F) double immunolabeled for coilin (red, A–F), TMG-cap (green, A–C), and fibrillarin (green, 
D–F). The profile of fluorescence signal across areas concentrating coilin shows whether colocalization exists with a 
marker of snoRNP (fibrillarin) or a marker of snRNP (TMG-cap) maturation processes. The intensity of the signal was 
analyzed with LSM510 software. 
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3. Nusinersen rescues the transcription rate of Chodl and ChAT pre-mRNAs. 
Due to the essential function of SMN in pre-mRNA splicing, various essential genes for αMN 
homeostasis may be affected in SMA mice models. The genes we chose to study the effects of Nusinersen 
on transcription rate were Chodl (chondrolectin) and ChAT (choline acetyl transferase), two important genes 
for αMN homeostasis that have been found to be highly expressed in αMNs, and whose expression 
becomes dysregulated in SMA. While, chondrolectin is involved in motor axon growth 61,62, choline acetyl 
transferase is the key enzyme in the synthesis of the main αMN neurotransmitter acetylcholine. For this 
reason choline acetyl transferase is commonly used as a marker of αMNs 63.  
To determine whether treatment with Nusinersen was able to rescue the transcription rate of these 
two genes, an analysis by qRT-PCR in spinal cord RNA extracts (P12) was performed. In SMN∆7 samples, 
pre-mRNA levels for both genes were significantly lower than in WT samples. Remarkably, the pre-mRNA 
levels in Nusinersen-treated SMN∆7 mice were comparable to that of WT (Figure 22). 
4. Nusinersen treatment normalizes the distribution of the protein synthesis 
machinery and polyadenylated mRNAs in SMN∆7. 
During the process of transcription, mRNA undergoes polyadenylation as one of the necessary 
modification steps before nuclear export. However, when a disturbance of the nuclear pre-mRNA 
processing occurs, those mRNAs are kept in the nucleus, where they accumulate 57. In the case of SMA, as 
previously reported by our laboratory and others, there is a marked perturbation of pre-mRNA splicing 
resulting in a defective mRNA maturation and the nuclear retention of incorrectly processed mRNAs in 
nuclear structures called “poly(A) RNA granules” (PARGs)56,57,64.  
In this work, we have previously shown that treatment with Nusinersen restores SMN protein levels 
in αMNs (Figure 15B, left panel). Since one of the major roles of SMN is the assembly of spliceosomal 
snRNPs, which is essential for the correct pre-mRNA splicing and mRNA export, we wanted to investigate 
Figure 22. (A, B) RT-PCR analysis of the expression of ChAT (A) and Chodl (B) pre-mRNAs in whole 
spinal cord RNA extracts from WT, SMN∆7 and nusinersen-treated SMN∆7 mice at P12. Both genes were 
normalized to the expression of GAPDH, and the results show that mRNA expression in Nusinersen-treated 
SMN∆7 mice is comparable to that of WT, while being demonstrably lower in untreated SMN∆7 animals. Bars 
represent the mean ± SD, *p < 0.05 and ***p < 0.0005 (n = 4 mice per group, Student’s t test analysis was 
performed using GraphPad). 
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whether Nusinersen treatment rescues the dysfunction in mRNA processing observed in SMN∆7 αMNs. 
For this purpose, we examined the distribution of poly(A) RNAs with in situ hybridization with a poly-dT 
probe. In the nucleus of WT αMNs, poly(A) RNAs appeared diffusely distributed, excluding the nucleolus, 
and accumulated in the nuclear speckles of splicing factors. In addition, poly(A) RNAs was diffusely 
distributed throughout the cytoplasm (Figure 23A and D). This distribution was mirrored by the 
Nusinersen-treated SMN∆7 αMNs (Figure 23C and F). In the case of vehicle-treated SMN∆7 αMNs, the 
cytoplasmic signal of polyadenylated mRNAs was notably reduced as compared to WT αMN. Interestingly, 
an important fraction of nuclear poly(A) RNAs were aggregated in PARGs (Figure 23B and E). In 
contrast, the presence of PARGs was significantly reduced in Nusinersen-treated αMNs (Figure 23G). The 
few remaining PARGs probably corresponded to granules formed previous to the Nusinersen 
administration, either during the fetal stage or the perinatal period.  
 
Figure 23. (A–F) FISH for poly(A) RNAs in WT (A, D), SMN∆7 (B, E) and Nusinersen-treated SMN∆7 (C, 
F) αMNs at P12. The pattern of poly(A) RNA hybridization signal was comparable between WT and Nusinersen-
treated SMN∆7 αMNs. Untreated SMNΔ7 αMNs had numerous PARGs and a notable reduction of FISH signal in 
the cytoplasm. PARGs were also found in Nusinersen-treated SMNΔ7 αMNs. (C, inset). Scale bars: 25 µm (A–C) and 
5 µm (D–F). (G) Graph comparing the mean percentages of αMNs with PARGs between the three different groups. 
Student’s t test analysis was performed using GraphPad (***p<0.0005). 
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The “sequestration” of polyadenylated mRNAs in PARGs may be a neuroprotective mechanism to 
prevent nuclear export and cytoplasmic translation of aberrant or unprocessed mRNA transcripts, which 
presumably are targeted for RNA decay. 
Finally, we decided to investigate whether Nusinersen-induced SMN upregulation and improved 
RNA homeostasis was also enough to restore protein synthesis machinery. For this purpose, we used the 
cytochemical staining for RNA-rich structures with propidium iodide (PI). As shown in Figure 24A, WT 
αMNs showed prominent areas of the cytoplasm enriched in rough endoplasmic reticulum and free 
polyribosomes, classically known as "Nissl bodies". A similar distribution pattern of Nissl bodies was seen 
in Nusinersen-treated SMN∆7 αMNs (Figure 24C). However, in vehicle-treated SMN∆7 αMNs a severe 
disruption of the Nissl bodies (central chromatolysis) was observed and almost all the αMNs exhibited 
eccentric nuclei (Figure 24B). 
.  
  
Figure 24. (A–C) Propidium iodide (PI) staining on dissociated spinal cord αMNs from WT (A), SMNΔ7 (B) 
and Nusinersen-treated SMNΔ7 mice (C) at P12. PI stains RNA-rich structures, showcasing the nucleolus and the 
protein synthesis machinery (Nissl substance). In the case of SMNΔ7 αMNs, there was a notable rescue of the Nissl 




As has been stated throughout this work and previous studies, αMNs are the main cellular target of 
SMA, although recent scientific evidence indicate the primary importance of other non-neural peripheral 
tissues and organs  2,3. In type I SMA patients and mouse models of the disease, the progressive degeneration 
of αMNs leads to muscle denervation and muscle atrophy, eventually culminating in death by respiratory 
failure 10. This degeneration is partially caused by the abnormal structural reorganization and dysfunction 
of nuclear compartments involved in RNA processing, as evidenced by the presence of PARGs and the 
depletion of CBs 57.  
Previous studies from our laboratory in the SMNΔ7 mouse model of type I SMA have shown that 
PARGs are formed by incorrectly processed mRNAs, which retain introns and accumulate in nuclear 
granules, preventing the nuclear export of aberrant transcripts for translation 65. In this context, the 
formation of PARGs acts as a neuroprotective mechanism, preventing the nuclear export of these aberrant 
transcripts to avoid spending extra energy in translating them and then clearing the resulting aberrant 
proteins 57,66. However, by the same token, this leads to lower amounts of mature mRNAs for translation, 
resulting in a dramatic disassembly of protein synthesis machinery in the cytoplasm.  The consequence is a 
reduced production of essential proteins for αMNs homeostasis which eventually leads to neuronal death 
56,57,65. 
The aim of this work is to assess the effects of Nusinersen in the SMNΔ7 mouse model of type I 
SMA. Previous studies have demonstrated that the administration of Nusinersen is linked to a longer 
lifespan and prevention of αMNs degeneration and myopathy 58,67. This has been corroborated by our 
results, where Nusinersen selectively restored SMN levels in the spinal cord and contributed to normalizing 
the growth curve and improving motor function at the late symptomatic stage in this mouse model (P12). 
Furthermore, we have also confirmed that Nusinersen preserves αMN population, and the nuclear 
organization of mRNA processing compartments, as well as the cellular protein synthesis machinery. 
One point where some studies seem to disagree, is whether SMN recovery in peripheral tissues can 
compensate for low levels of SMN in the spinal cord. Studies with the ASO10-27 seem to indicate that is 
the case 68, however, although a small amount of Nusinersen may be cleared with cerebrospinal fluid into 
the blood, our team and others indicate otherwise 69. Our results support that the recovery of SMN levels 
in spinal cord is essential for αMN and skeletal myofiber homeostasis.  In fact, the myofiber size distribution 
and the oxidative pattern of myofibers, estimated with the SDH assay, are rescued in our model only 
through spinal cord recovery, without normalizing the levels of SMN in muscle. These differences may be 
caused by the use of different mouse models, and treatment protocols for the ASO. 
As for the molecular mechanism behind Nusinersen, by binding to the ISS-N1 in SMN2 pre-mRNA 
it is essential in SMN2 splicing regulation, favoring the inclusion of exon 7 into the full-length transcript 
58,67,70. In the treated SMNΔ7 group we found a recover of both number and molecular composition of 
CBs. CBs are transcription-dependent nuclear organelles, round shaped and approximately 0,5 µm of 
diameter,  in which snRNP biogenesis is substantially more efficiently than in nucleoplasm 23. In SMA, since 
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they lack enough SMN, CBs become disrupted, resulting in a severe inhibition of spliceosomal snRNP 
biogenesis and reduced availability of mature snRNP for the spliceosome assembly 22. Depletion of CBs 
leads to a decrease in proper pre-mRNA splicing of several mRNAs essential for αMNs physiology, a lack 
of those in the cell and eventual αMN degeneration. For this reason, the depletion of CBs and the 
relocalization of coilin, the main molecular marker of CBs, as perinucleolar caps, are considered an early 
signs of neuronal dysfunction 37,56,60. 
As evidence of this Nusinersen-induced recovery of transcription, our results show that Chodl and 
ChAT mRNAs – both essential for αMN survival 61,62– are expressed at normal levels in Nusinersen-treated 
SMNΔ7 mice. This is consistent with the increase in canonical CBs, and the recovery of the protein 
synthesis machinery 18. Moreover, we show that Nusinersen rescues the normal compartmentalization of 
polyadenylated mRNAs. It is well established that all mRNAs, except for histone mRNAs, are 
polyadenylated in the nucleus as part of a nuclear export signal, which is also needed for translation 71. In 
SMA and other diseases, these polyadenylated mRNAs have been shown to form granules in the 
nucleoplasm (PARGs) 57. Our results suggest that PARGs contain unspliced or aberrant transcripts that 
become sequestered in the nucleus. In this context, the formation of PARGs has been associated with a 
splicing perturbation partially caused by a defective snRNP biogenesis in CBs. Indeed, in Nusinersen-
treated SMNΔ7 mice, in which CB number is normalized in αMNs, the incidence of PARGs is very reduced 
when compared to untreated SMNΔ7 neurons depleted of CBs. We believe that the reason why PARGs 
do not completely disappear, is because low levels of SMN start to affect the neurons in utero and some 
PARGs can persist from the fetal or neonatal period, prior to Nusisnersen administration. Therefore, the 
reduced number of PARGs found in Nusinersen-treated animals is consistent with the rescue of CB 
number, as well as the recovery of mRNA processing machinery and export. 
In conclusion, in this work we demonstrate that there is a Nusinersen-dependent rescue of (i) 
molecular assembly of canonical CBs, (ii) expression of Chodl and ChAT primary transcripts, (iii) nuclear 
and cytoplasmic distribution of polyadenylated mRNAs and (iv) the organization of the protein synthesis 
machinery in αMNs of the SMNΔ7 mouse. This recovery seems essential for neuronal homeostasis and 
survival. Moreover, the αMN survival has been shown to partially recover the myopathy present in this 
disease. The reason for the incomplete recovery of the peripheral tissues, particularly of the muscle, may 
be the ICV administration of the ASO, which prevents Nusinersen from reaching the tissues outside of the 
CNS.  
In light of these findings, further studies may focus on Nusinersen’s effect on skeletal myofiber 
pathology. SMNΔ7 myofibers show disruption of the sarcomeres and actin dynamics. To this effect, 
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nusinersen ameliorates motor 
function and prevents motoneuron 
cajal body disassembly 
and abnormal poly(A) RnA 
distribution in a SMA mouse model
María t. Berciano1,4,5,8, Alba Puente‑Bedia2,8, Almudena Medina‑Samamé3, 
José C. Rodríguez‑Rey1,4, Jordi Calderó6, Miguel Lafarga3,4,5 & Olga Tapia4,5,7*
Spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disease 
characterized by degeneration of spinal cord alpha motor neurons (αMNs). SMA is caused by the 
homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene, resulting in reduced 
expression of SMN protein, which leads to αMN degeneration and muscle atrophy. The majority 
of transcripts of a second gene (SMN2) generate an alternative spliced isoform that lacks exon 7 
and produces a truncated nonfunctional form of SMN. A major function of SMN is the biogenesis 
of spliceosomal snRNPs, which are essential components of the pre‑mRNA splicing machinery, 
the spliceosome. In recent years, new potential therapies have been developed to increase SMN 
levels, including treatment with antisense oligonucleotides (ASOs). The ASO‑nusinersen (Spinraza) 
promotes the inclusion of exon 7 in SMN2 transcripts and notably enhances the production of full‑
length SMN in mouse models of SMA. In this work, we used the intracerebroventricular injection of 
nusinersen in the SMN∆7 mouse model of SMA to evaluate the effects of this ASO on the behavior 
of Cajal bodies (CBs), nuclear structures involved in spliceosomal snRNP biogenesis, and the cellular 
distribution of polyadenylated mRNAs in αMNs. The administration of nusinersen at postnatal day (P) 
1 normalized SMN expression in the spinal cord but not in skeletal muscle, rescued the growth curve 
and improved motor behavior at P12 (late symptomatic stage). Importantly, this ASO recovered the 
number of canonical CBs in MNs, significantly reduced the abnormal accumulation of polyadenylated 
RNAs in nuclear granules, and normalized the expression of the pre‑mRNAs encoding chondrolectin 
and choline acetyltransferase, two key factors for αMN homeostasis. We propose that the splicing 
modulatory function of nusinersen in SMA αMN is mediated by the rescue of CB biogenesis, resulting 
in enhanced polyadenylated pre‑mRNA transcription and splicing and nuclear export of mature 
mRnAs for translation. our results support that the selective restoration of SMn expression in the 
spinal cord has a beneficial impact not only on αMNs but also on skeletal myofibers. However, the 
rescue of SMn expression in muscle appears to be necessary for the complete recovery of motor 
function.
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease that is considered the main 
genetic cause of infant mortality. SMA is caused by the homozygous loss or mutation of the survival of motor 
open
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neuron 1 (SMN1) gene, leading to reduced levels of full-length SMN protein. SMN depletion triggers the selective 
degeneration of lower alpha motor neurons (αMNs), resulting in preferential atrophy of the proximal skeletal 
muscles with weakness and muscle  paralysis1–3.
In addition to the SMN1 gene, humans ubiquitously express one or several copies of a closely related paralog 
gene called SMN2. This gene encodes a full-length SMN protein but presents one consistent difference, that is, 
the transition C to T (C6T) in exon 7. This change deactivates a splicing enhancer and introduces a splicing 
silencer, resulting in the exclusion of exon 7 in most SMN2  transcripts4,5. These transcripts are translated into 
a truncated SMN (SMNΔ7) protein that is rapidly ubiquitylated and degraded by the proteasome  system5–7. 
Although the expression of the SMN2 gene is residual under physiological conditions, the deletion or mutation 
of SMN1 confers the number of copies of SMN2 considerable importance in modifying the severity of SMA 
phenotypes. Thus, the most severe and frequent SMA is that of type I, which usually has two copies of the SMN2 
gene. Patients with type II or III SMA have a higher copy number of SMN28–11.
The functional full-length SMN protein homo-oligomerizes and forms a stable complex (SMN-complex) with 
Gemin2-8 and Unrip  proteins3,12. The SMN complex acts as a molecular chaperone to assist the cytoplasmic stage 
of the assembly of spliceosomal U snRNPs, which are essential splicing factors of the  spliceosome13,14. Linked 
to this function of the SMN complex, the Cajal body (CB) is particularly relevant, given its implication in the 
biogenesis of both spliceosomal U snRNPs and nucleolar  snoRNPs15–18. In particular, the enrichment of the CB 
in spliceosomal U snRNPs is consistent with the growing evidence of a spatial association of this organelle with 
certain transcriptionally active genomic loci of  snRNAs17,19–21. Moreover, the physical association of CBs with 
the dense fibrillar component of the nucleolus, the site of synthesis and early processing of pre-rRNAs provides 
a molecular link for a nucleolus-CB  interaction18,22–24.
In this context, recent studies from our laboratory have shown that reduced SMN levels in αMNs of a type I 
SMA patient and the SMN∆7 mouse model induce nuclear features of αMN degeneration, including depletion 
of canonical CBs, nucleolar stress and altered mRNA  processing25,26. The dysfunction of mRNA processing in 
this SMA mouse is also characterized by (i) the early and progressive accumulation of polyadenylated mRNAs 
in nuclear granules called PARGs (“poly(A) RNA granules”), (ii) the increase in intron-containing pre-mRNAs, 
and (iii) the disruption of the protein synthesis  machinery25–27. In fact, the dysfunction of RNA metabolism 
has enabled us to redefine the SMA as a RNA pathology, although it could also be considered a  spliceopathy28.
To explore whether normalizing SMN expression in SMN∆7 αMNs during the neonatal period, prior to 
αMN degeneration, prevents CB depletion and splicing alterations with nuclear retention of unspliced pre-
mRNAs in PARGs, we treated SMN∆7 mice with the antisense oligonucleotide (ASO) nusinersen (Spinraza). This 
2′-O-methoxyethyl (MOE)-modified ASO was designed to increase full-length SMN protein levels by promot-
ing the inclusion of exon 7 in SMN2 mRNAs. Nusinersen binds to a target site within intron 7, ≅ 10 nucleotides 
downstream of the 5′-splice site, known as ISS-N1 (intronic splicing silencer N1)29. This interaction displaces 
the splicing suppressor proteins hnRNP A1/A2 and enables spliceosomal U1 snRNPs to bind to the 5′-splice site, 
thereby promoting the inclusion of exon 7 in SMN2  transcripts29–35. Previous studies in mouse SMA models have 
demonstrated that nusinersen, when administered directly into the cerebrospinal fluid (CSF), prolongs animal 
survival and prevents αMN and skeletal muscle  pathology31,36,37.
Our results in SMN∆7 αMNs show that the intracerebroventricular (ICV) injection of nusinersen at the 
neonatal period (postnatal day [P] 1) (i) improves motor function, (ii) rescues the CB number, (iii) increases 
the expression of pre-mRNAs encoding chondrolectin (Chodl) and choline acetyltransferase (Chat), two key 
factors for αMN  homeostasis38, and (iv) reduces the nuclear retention of polyadenylated mRNAs into PARGs at 
the symptomatic P12 stage. These effects are accompanied by the restoration of the protein synthesis machinery, 
supporting an effective recovery of mRNA processing and translation.
Results
Treatment with ASO‑nusinersen (Spinraza) robustly rescues the growth curve, enhances 
motor function and dramatically reduces αMN loss. Based on previous studies from our laboratory, 
we have established two temporary windows that demarcate the clinical evolution of SMNΔ7 mice: (i) the pre-
clinical phase (from P0 to P6) and (ii) the clinical phase (from P7 to P12), when the clinical symptoms appear 
and progress, commonly leading to the death of mice between P12 and P14.
The ICV administration of nusinersen (Fig. 1A) at P1 was well tolerated with no obvious signs of toxicity or 
drug-related death. First, we studied the clinical evolution of SMN∆7 mice treated or not treated with nusin-
ersen. We evaluated the growth curve of mice by performing daily measurement of the body weight from P1 to 
P12 (Fig. 1C). We noticed that nusinersen treatment had a highly significant impact on body weight gain with 
a growth curve comparable to that of vehicle-treated WT (hereafter referred to as WT) mice from P6 to P12 
(Fig. 1B–D). In fact, nusinersen-treated SMN∆7 mice weighed approximately twice as much as the vehicle-treated 
mice (hereafter referred to as SMN∆7) at P12 (Fig. 1B–D). On the other hand, nonsignificant differences in body 
weight were found between WT animals treated with vehicle and nusinersen, indicating that the administration 
of this ASO does not modify body weight under physiological conditions (“body weight follow-up × genotype”: 
 F(4,40) = 84.23, p < 0.0001; “body weight follow-up × nusinersen treatment”:  F(4,40) = 57.64, p < 0.0001).
Next, we investigated whether nusinersen treatment improves motor functions in SMN∆7 mice by using the 
righting reflex test. This test evaluates the overall muscle strength and motor coordination, which are severely 
affected in SMA mice due to weakness of the limb and trunk muscles. The test assesses the time taken for the 
mouse placed on its back to right itself through 180° to a maximum of 30 s39. Whereas the SMNΔ7 mice did not 
acquire the righting reflex during the neonatal period studied (P1-P12) (Fig. 1E), both WT mice and nusinersen-
treated SMNΔ7 mice acquired this motor reflex as early as P3, although the latter showed a temporary delay in 
the completion of the test (Fig. 1E) (“righting reflex follow-up × genotype”:  F(3,39) = 14.85, p < 0.0001; “righting 
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Figure 1.  (A) Scheme illustrating the intrathecal injection point of the ASO-nusinersen (Spinraza). (B,C) 
Images showing differences in body size between WT and SMNΔ7 mice (B) and WT and nusinersen-treated 
SMNΔ7 mice (C) at P12. (D) Comparative analysis of body weight (mean ± SD) among WT, SMNΔ7 and 
nusinersen-treated SMNΔ7 mice from P0 to P12 (n = 8 mice per group). #p < 0.01, ###p < 0.0001: WT vs. 
SMN∆7; ***p < 0.0001: vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7. (E) Response to righting 
motor reflex acquisition (mean ± SD) at the indicated postnatal periods. Note how nusinersen treatment 
ameliorates the motor response in SMNΔ7 mice when compared to untreated SMNΔ7 mice (n = 8 mice per 
group). ###p < 0.0001: WT vs. SMN∆7; ***p < 0.0001: vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7. 
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reflex follow-up × nusinersen treatment”:  F(3,39) = 72.77, p < 0.0001). Moreover, whereas SMNΔ7 mice exhibited 
very severe muscular atrophy, which affects the ability of moving, nusinersen-treated SMNΔ7 mice exhibited 
moderate hindlimb atrophy and preserved ambulation capacity; however, moderate hindlimb paresis was notice-
able in these animals compared to WT mice (see Supplementary Video S1).
To determine whether the clinical improvement of nusinersen-treated SMNΔ7 mice was produced by nor-
malizing SMN levels in the spinal cord, we performed a western blot analysis in tissue lysates at P12. The results 
in SMNΔ7 mice showed that nusinersen treatment increased SMN expression by 2.5 times in the spinal cord 
compared with untreated animals. The increase reached approximately 70% of SMN levels from WT samples 
(Fig. 1O). Next, we investigated whether nusinersen treatment modified SMN protein levels in muscle, a periph-
eral tissue essentially involved in SMA  pathogenesis40,41. Western blot analysis of the tibialis anterior (TA) muscle 
lysates revealed that the neonatal ICV delivery of nusinersen in SMNΔ7 mice did not increase SMN expression 
in muscle at P12 (Fig. 1O). This result suggests that the therapeutic agent did not cross the blood–brain barrier 
in neonatal mice, and consequently, the beneficial clinical effect of nusinersen treatment should be mainly due 
to increased SMN expression in the spinal cord. Consistent with this view, SMN immunolabeling of dissociated 
αMNs showed that the staining pattern in nusinersen-treated SMNΔ7 neurons was similar to that found in WT 
neurons. SMN was diffusely distributed in the cytoplasm with a moderate intensity of fluorescent signal. In the 
nucleus SMN was specifically concentrated in CBs (Fig. 1F,H). Interestingly, αMNs from SMNΔ7 mice exhibited 
a notably weak cytoplasmic signal of SMN, and CBs were rarely observed (Fig. 1G).
To further understand the effects of nusinersen treatment on the survival of SMNΔ7 αMNs, we performed 
a quantitative analysis on spinal cord cryosections (lumbosacral region) immunostained for ChAT, a marker of 
αMNs40,42. As expected, nusinersen treatment preserved the population of αMNs in the anterior horn (Fig. 1I,K). 
Thus, no significant differences in the mean number of αMNs per section were found between WT mice and 
nusinersen-treated SMNΔ7 animals (Fig. 1P). In contrast, differences were significant when these two groups 
were compared with SMNΔ7 mice, which had an overt depletion of αMNs (Fig. 1J–K,P).
Since nusinersen treatment prevents αMN death and presumably the formation and maintenance of the neu-
romuscular junction, we next investigated whether this ASO can prevent muscle atrophy induced by neurogenic 
myopathy in SMNΔ7 mice. We estimated the myofiber size distribution on cross-cryosections of the TA muscle 
using the histochemical enzymatic assay for succinate dehydrogenase (SDH), a marker of mitochondrial oxidative 
 activity40. Interestingly, despite the reduced SMN expression in the muscle of nusinersen-treated SMNΔ7 mice, 
nonsignificant differences in myofiber diameter were found between WT mice and nusinersen-treated SMNΔ7 
mice at P12 (Fig. 1Q). However, a significant reduction in the myofiber diameter was detected in SMNΔ7 mice 
compared with nusinersen-treated mice (Fig. 1Q). Moreover, SDH histochemistry revealed that both WT and 
nusinersen-treated SMNΔ7 myofibers exhibited a staining checkboard pattern of a mixed muscle with a similar 
proportion of myofibers whose SDH oxidative activity corresponded to type 1, 2A and 2X (Fig. 1L,N). In contrast, 
vehicle-treated SMNΔ7 myofibers were clearly atrophic with reduced diameter and an oxidative intensity of stain 
predominantly corresponding to aerobic type 1 myofibers (Fig. 1M,Q). It should be noted that the administration 
of nusinersen in WT mice did not change the SDH pattern detected in vehicle-treated WT mice (data not shown).
Nusinersen treatment prevents the disruption and loss of canonical Cajal bodies (CBs) in αMNs 
of the SMA mouse. The CB is a transcription-dependent nuclear organelle whose number and size accom-
modate the cellular demands of pre-mRNA  splicing16,18. Consistent with this notion, our previous studies in 
αMNs from an SMA patient and the SMNΔ7 mouse have shown that the αMN degeneration caused by SMN 
In C,D, data were analyzed by a one-way ANOVA, followed by the Bonferroni post hoc test using SPSS. 
(F–H) Immunodetection of SMN reveals that nusinersen treatment rescues the typical SMN staining pattern 
in WT αMNs, which appears diffuse in the cytoplasm and concentrated in CBs (F,H). In contrast, αMNs 
from the untreated SMNΔ7 mouse exhibit a very weak cytoplasmic SMN signal and CB depletion (G). (I–K) 
Immunodetection of ChAT in the anterior horn of spinal cord showing how nusinersen treatment increases 
αMN number in the SMNΔ7 mouse compared with the untreated SMNΔ7 animals. (L–N) SDH histochemical 
staining of transverse cryosections of the TA muscle from WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice 
at P12. In SMNΔ7 mice, this treatment rescues the myofiber phenotype found in WT muscle with a similar 
distribution of type 1, 2A and 2X myofibers (L,N). Note that the nusinersen-untreated SMNΔ7 muscle is 
preferentially composed of smaller type 1 myofibers (M). (O) Western blot analysis of SMN protein levels in 
whole spinal cord and skeletal muscle lysates at P12. Note the reduction in SMN levels in the spinal cord and 
muscle of the SMNΔ7 mouse and the recovery of SMN expression in the spinal cord but not in the muscle upon 
nusinersen treatment. SMN bands were normalized to lamin, and the relative expression levels of SMN were 
calculated using ImageJ. Full-length blots are presented in Supplementary Information. (P) Quantitative analysis 
of the number of αMNs (mean ± SD) in transverse cryosections of the spinal cord immunostained for ChAT. 
αMN counts were performed on the hemispinal cords of WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice 
at P12. *p < 0.05 when WT and SMN∆7 or vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7 mice were 
compared (n = 4 per group, Student’s t test analysis was performed using GraphPad). (Q) Quantitative analysis 
of the myofiber diameter (mean ± SD) on transverse cryosections of the TA muscle histochemically stained for 
SDH detection. Measurements were performed in WT, SMNΔ7 and nusinersen-treated SMNΔ7 mouse muscles 
at P12. **p < 0.005 when WT and SMN∆7 or vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7 mice were 
compared (n = 4 per group, Student’s t test analysis was performed using GraphPad). Scale bars: 10 µm (F–H), 
30 µm (I–K) and 5 µm (L–N).
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deficiency includes an early depletion of canonical CBs and relocalization of coilin as perinucleolar caps and/or 
within the  nucleolus18,25. Based on this observation, we considered that the disruption of CBs is an early nuclear 
sign of αMN degeneration in SMA.
Having established that nusinersen treatment preserves the normal population of αMNs and increases SMN 
protein levels in the spinal cord, we next investigated whether this agent rescues the formation and assembly of 
canonical CBs in SMNΔ7 αMNs. Double immunolabeling for coilin and SMN revealed the typical cytoplasmic 
distribution of SMN and the regular presence of canonical CBs, which concentrate coilin and  SMN16,18, in both 
WT and nusinersen-treated SMNΔ7 αMNs (Fig. 2A,C,D,F). Moreover, these canonical CBs showed a preferential 
association with the nucleolus (Fig. 2D,F), as previously reported in other mammalian  neurons18,22. In contrast, 
the reduced cytoplasmic SMN staining observed in SMNΔ7 αMNs was accompanied by depletion of canonical 
CBs and formation of coilin-positive perinucleolar caps, where SMN was not or only slightly detected (Fig. 2B,E). 
Plots of linear profiles of coilin and SMN fluorescence intensity signals confirmed the colocalization of both 
molecules in canonical CBs and the absence of SMN in the perinucleolar caps (see Supplementary Fig. S2, A–C).
The neuroprotective effect of nusinersen treatment on SMNΔ7 αMNs was validated by a quantitative analysis 
of the mean number of CBs per nucleus in neuronal dissociates coimmunostained for coilin and SMN. Nonsig-
nificant differences in the mean number of canonical CBs were detected between WT and nusinersen-treated 
SMNΔ7 αMNs at P12 (n = 4; 2.44 ± 0.34 vs. 2.94 ± 0.54; p = 0.18) (Fig. 2A,C). However, in the neurodegenerative 
phase of SMNΔ7 αMNs (P12), CB number was dramatically reduced compared with WT αMNs (n = 4; 0.08 ± 0.28 
in SMNΔ7, vs. 2.44 ± 0.34 in WT; p = 0.00009) (Fig. 2A,B).
To further characterize the molecular organization of CBs, we performed double immunolabeling for coilin 
in combination with either TMG-cap, a marker of spliceosomal snRNPs that recognizes the 5′ end of  snRNAs43, 
or fibrillarin, a nucleolar snoRNP shared with the  CB18,22. As expected, both TMG-cap and fibrillarin signals 
colocalized with coilin in the CBs of WT αMNs and nusinersen-treated SMNΔ7 αMNs (Fig. 2G,I,J,L; Supple-
mentary Fig. S2D, F, G and I), indicating that these nuclear bodies are canonical functional CBs that concentrate 
splicing factors and snoRNPs in addition to coilin and  SMN16,44. In contrast, perinucleolar caps of SMNΔ7 αMNs 
lacked a TMG-cap signal and had weak staining for fibrillarin (Fig. 2H,K).
Finally, it is noteworthy that Gems, coilin-negative and SMN-positive nuclear  bodies45,46 are conspicuously 
absent in αMNs in all experimental groups studied.
nusinersen treatment rescues the transcription rate of Chodl and ChAT pre‑mRNAs. Previous 
studies have demonstrated widespread defects in transcription and pre-mRNA splicing of essential genes for 
αMN homeostasis in cellular and animal models of  SMA27,47–51. Among these genes, Chodl (chondrolectin) and 
ChAT (choline acetyltransferase) are highly expressed in αMNs, playing crucial functions in motor axon growth 
and neurotransmission,  respectively38,52. Moreover, Chodl and ChAT are major gene products with dysregulated 
expression in SMA mouse αMNs27,38.
To determine whether nusinersen treatment is able to rescue the transcription rate of Chodl and ChAT, we 
analyzed the expression levels of both pre-mRNAs by qRT-PCR in spinal cord RNA extracts at P12. We found a 
significant reduction in Chodl and ChAT pre-mRNAs in SMNΔ7 samples compared with WT samples (Fig. 3A). 
Remarkably, nusinersen treatment in SMNΔ7 mice rescued the transcription rates of both genes, which reached 
pre-mRNA levels comparable to WT ones (Fig. 3A).
Nusinersen treatment normalizes the distribution of the protein synthesis machinery and pol‑
yadenylated mRNAs in SMNΔ7 mice. Our group and others have previously shown a severe perturba-
tion of the protein synthesis machinery with a remarkable nuclear and cytoplasmic redistribution of polyade-
nylated RNAs and chromatolysis in αMNs of SMA mouse  models26,27,53. On this basis, we investigated whether 
nusinersen treatment is able to prevent this severe perturbation of neuronal homeostasis in SMNΔ7 αMNs. 
Cytochemical staining of RNA-rich structures with propidium iodide revealed prominent Nissl bodies (cyto-
plasmic areas enriched in rough endoplasmic reticulum and free  polyribosomes54) distributed throughout the 
cytoplasm in both WT and nusinersen-treated SMNΔ7 αMNs (Fig. 3C,E). In contrast, most αMNs from SMNΔ7 
mice exhibited different degrees of disruption of Nissl bodies, particularly central chromatolysis (Fig. 3D).
Next, we analyzed whether nusinersen treatment preserves the normal distribution of poly(A) RNAs, which 
include all mRNAs with the exception of histone mRNAs, as an indicator of proper nuclear mRNA processing 
and export to the cytoplasm. In situ hybridization with the poly-dT probe revealed that poly(A) RNA appeared 
diffusely distributed throughout the nucleus (excluding the nucleolus), highly concentrated in nuclear speckles 
and accumulated in extensive cytoplasmic areas of WT αMNs (Fig. 3F,I). In contrast, SMNΔ7 αMNs displayed 
a prominent nuclear aggregation of poly(A) RNAs in PARGs (Fig. 3G,J), round sharply defined bodies previ-
ously reported in mouse SMA αMNs and other neurons under stress  conditions27,55,56. In addition, we found a 
cytoplasmic reduction in the poly(A) RNA hybridization signal, suggesting a decreased availability of mRNA 
for translation (Fig. 3G,J). Interestingly, SMNΔ7 αMNs treated with nusinersen tended to normalize the nuclear 
and cytoplasmic distribution of polyadenylated mRNAs observed in WT αMNs (Fig. 3H,K). Furthermore, the 
proportion of αMNs carrying PARGs was significantly reduced in nusinersen-treated SMNΔ7 mice compared to 
SMNΔ7 animals (Fig. 3B). Since the formation of PARGs begins during the perinatal  period27, probably before 
drug administration, we assume that the reduced number of PARGs found in nusinersen-treated SMNΔ7 αMNs 
is a remnant of the fetal or perinatal stage. We suggest that the nuclear retention of poly(A) RNA into PARGs 
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Figure 2.  (A–F) Confocal images of dissociated αMNs from WT (A,D), SMN∆7 (B,E) and nusinersen-
treated SMN∆7 mice (C,F) double immunolabeled for coilin (red) and SMN (green). Note that coilin and 
SMN colocalize in canonical CBs from WT and nusinersen-SMNΔ7 αMNs (D,F), whereas coilin-positive and 
SMN-negative perinucleolar caps are detected in αMNs from the vehicle-treated SMNΔ7 mouse. (G–L) Double 
immunolabeling for coilin and TMG-cap (G–I) or fibrillarin (J–L) in αMNs from WT, SMNΔ7 and nusinersen-
treated SMNΔ7 mice. Coilin colocalizes with both TMG-cap and fibrillarin in canonical CBs from WT and 
nusinersen-treated SMNΔ7 αMNs (G,I,J,L). In contrast, the perinucleolar caps of SMNΔ7 αMNs are free from 
the splicing factor marker TMG-cap (H) and exhibit a weak fibrillarin signal (K). Scale bars: 20 µm (A–C), 5 µm 
(D–I) and 2.5 µm (J–L).
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Figure 3.  (A) RT-PCR analysis of the expression of Chodl and ChAT pre-mRNAs in whole spinal cord RNA 
extracts from WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice at P12. Bars represent the mean ± SD, *p < 0.05 
and ***p < 0.0005 (n = 4 mice per group, Student’s t test analysis was performed using GraphPad). (B) The mean 
percentages of αMNs with PARGs were 1.38% in WT mice and 35.73% in SMN∆7 mice. Nusinersen treatment 
in SMN∆7 mice significantly reduced the proportion of αMNs with PARGs to 12.04%. p values of WT vs. 
SMN∆7 αMNs: 1.78 × 10–6 (***p < 0.0005); SMN∆7 vs. nusinersen-treated αMNs: 2.8 × 10–6 (***p < 0.0005); 
and WT vs. nusinersen-treated SMN∆7: 0.0046 (**p < 0.005) (Student’s t test analysis was performed using 
GraphPad). (C–E) Dissociated spinal cord αMNs from WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice 
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Discussion
It is well established that αMNs are the main physiopathological cellular targets of SMA, although increasing 
evidence has revealed the primary importance of other peripheral  tissues41,57,58. Degeneration of αMNs leads to 
severe muscular atrophy by denervation, muscle paralysis and premature death by respiratory failure in type I 
SMA, the most severe form of the disease.
In our previous studies in the SMNΔ7 mouse model of SMA, we observed that SMN depletion in αMNs 
during the symptomatic postnatal stage severely impacts nuclear compartments involved in pre-rRNA and 
pre-mRNA  processing26. Moreover, polyadenylated mRNAs are aggregated in PARGs, reflecting an alteration of 
mRNA splicing with increased intron retention, abnormal accumulation of incorrectly processed mRNAs and 
inhibition of the nuclear export of mature  mRNAs27. This neuronal dysfunction leads to a neurodegenerative 
process, which is characterized by reduced availability of mature mRNAs for translation, progressive disruption 
of the protein synthesis machinery and, ultimately, neuronal  death26,27,53.
In this study, we demonstrate that the therapeutic outcome of the ICV administration of nusinersen (Spin-
raza) in the SMNΔ7 mouse model of type I SMA is mediated by the selective restoration of SMN levels in the 
spinal cord but not in muscle. Nusinersen treatment in neonatal SMNΔ7 mice normalizes the growth curve and 
improves motor function at the late symptomatic stage (P12). These effects are mediated by preserving the normal 
population of αMNs, as well as the nuclear organization of mRNA processing compartments and the protein 
synthesis machinery. Consistent with these findings, previous studies in mouse SMA models have demonstrated 
that nusinersen, when administered directly into the CSF, prolongs animal survival and prevents αMN and skel-
etal muscle  pathology31,36,37. However, a recent study using the systemic administration of ASO10-27 in SMA 
mice supports that peripheral tissues play an essential role in SMA  pathology41. The authors indicate that the 
increase in SMN exclusively in peripheral tissues compensates for its deficiency in the spinal cord and preserves 
αMNs. In our study, the improvements in body weight, motor function and survival in SMN∆7 mice treated with 
nusinersen were associated with a notable increase in SMN levels in the spinal cord but not in the TA muscle, 
which exhibited reduced SMN levels, similar to those detected in untreated SMN∆7 mice. Although a fraction 
of nusinersen injected into cerebral ventricles may be cleared with CSF into the blood and influence peripheral 
tissues, our results and those from other  authors59 support that the increase in SMN in the spinal cord is required 
for the rescue of αMN and skeletal myofiber homeostasis. In fact, we observed that both the skeletal myofiber 
size distribution and the SDH oxidative staining pattern of myofibers are rescued, despite having reduced SMN 
levels in muscle. However, the relative importance of SMN restoration in spinal cord versus peripheral tissues 
in the therapeutic outcome reported in separate studies may be notably influenced by differences in transgenic 
mouse models of SMA and treatment protocols with ASO.
Consistent with the essential role of nusinersen in the splicing regulation of the SMN2 gene, promoting the 
inclusion of exon 7 in the SMN2 mRNAs and their translation in full-length SMN  protein30–32,34,60, we detected 
a recovery in the number and molecular composition of CBs. This neuroprotective mechanism, mediated by 
the increased expression of SMN in αMNs, can promote the molecular assembly of canonical CBs, which are 
enriched in coilin, SMN and spliceosomal  snRNPs15,16,43. CBs are transcription-dependent nuclear organelles 
involved in spliceosomal snRNP biogenesis required for pre-mRNA  splicing15,16,61. Depletion of CBs and coilin 
relocation in the form of perinucleolar caps or within the nucleolus are reliable early signs of neuronal dysfunc-
tion in many neurodegenerative disorders, including  SMA18,25,26,62. It is noteworthy that snRNPs are essential 
components of the spliceosome, the macromolecular machine for pre-mRNA  splicing14, and their biogenesis is 
considerably more efficient in CBs than in the  nucleoplasm63. In fact, depletion of CBs in cells derived from SMA 
patients correlates with reduced U4/U6-U5 tri-snRNP assembly, a key maturation step of spliceosomal snRNPs, 
and with splicing  alterations47,64. A recent study reported an increase in the number of Gems (SMN-positive 
and coilin- and snRNP-negative nuclear bodies of unknown  function45,46) in αMNs following the subcutaneous 
administration of ASO10-27 in a mouse model of  SMA41. However, in our study, we have never observed Gems 
but canonical CBs induced by nusinersen treatment in SMA mice.
In nusinersen-treated SMNΔ7 mice, the transcription rate activation of Chodl and ChAT, two genes dys-
regulated in SMA that are essential for αMN  survival38,52, is consistent with the increase in CBs, whose numbers 
must be accommodated to the neuronal demand for pre-mRNA  processing44. In this context, it was also note-
worthy that nusinersen treatment in SMNΔ7 mice also rescued the normal organization of the protein synthesis 
machinery (Nissl bodies) and substantially recovered the nuclear and cytoplasmic compartmentalization of 
polyadenylated mRNAs. It is well established that all mRNAs, except for histone mRNAs, are polyadenylated in 
the nucleus, and the poly(A) tail is necessary for efficient mRNA export and  translation65. The regulation of the 
nuclear and cytoplasmic compartmented transcriptomes is essential for cell homeostasis. Indeed, in this study 
and  previously27, we have demonstrated the nuclear accumulation of polyadenylated RNAs into PARGs, which is 
at P12 stained with propidium iodide (PI) to demonstrate the RNA-rich nucleolus and protein synthesis 
machinery (Nissl substance). Note the rescue of prominent Nissl bodies in nusinersen-treated SMNΔ7 αMNs 
(E) and the central chromatolysis in untreated SMNΔ7 αMNs (D). (F–H) FISH for poly(A) RNAs in WT, 
SMNΔ7 and nusinersen-treated SMNΔ7 αMNs at P12. A similar pattern of poly(A) RNA hybridization signal 
was observed in WT and nusinersen-treated SMNΔ7 αMNs: diffuse in the nucleus, excluding the nucleolus, 
concentrated in nuclear speckles of splicing factors and diffuse in the cytoplasm (F,H,I,K). Note the abundance 
of nuclear poly(A) RNA-positive granules (PARGs) in numerous SMNΔ7 αMNs, which was accompanied by 
a substantial reduction of the hybridization signal in the cytoplasm (G,J). PARGs were occasionally found in 
nusinersen-treated SMNΔ7 αMNs (H, inset). Scale bars: 15 µm (C–E), 25 µm (F–H) and 5 µm (I–K).
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associated with intron retention. Nuclear retention of polyadenylated mRNAs may prevent the nuclear export of 
unspliced or inappropriately expressed transcripts and attenuate translation and energy consumption to maintain 
energy homeostasis under stress  conditions27,66. Moreover, nuclear retention of polyadenylated mRNAs may be 
linked to defective snRNP biogenesis in CBs. In this sense, a recent  study67 reported that the inhibition of U4 
snRNP biogenesis, a key component for U4/U6-U5 tri-snRNP assembly in  CBs68, results in the abnormal nuclear 
accumulation of polyadenylated mRNAs. Importantly, the ICV administration of nusinersen in SMN∆7 mice 
substantially reduced the formation of PARGs and restored the nuclear and cytoplasmic compartmentalization of 
polyadenylated mRNAs in αMNs. This neuronal response is consistent with a substantial recovery of CB number 
and pre-mRNA processing and export of mature polyadenylated mRNAs for their translation.
In conclusion, the nusinersen (Spinraza)-dependent rescue of the (i) molecular assembly of canonical CBs, 
(ii) expression of Chodl and ChAT primary transcripts, (iii) nuclear and cytoplasmic distribution of polyade-
nylated mRNAs, and (iv) organization of protein synthesis machinery in αMNs of the SMNΔ7 mouse appears 
to be essential for maintaining neuronal homeostasis and survival. The increase in SMN expression in the spinal 
cord partially prevents the severe SMA myopathy induced by αMN degeneration. We suggest that the incomplete 
recovery of neuromuscular performance in nusinersen-treated SMNΔ7 mice with moderate hindlimb paresis 
may result from reduced SMN expression in muscle. Further studies will be addressed to investigate the potential 
role of nusinersen treatment on skeletal myofibers, particularly on the focal disruption of the sarcomere archi-
tecture and actin dynamics observed in the SMNΔ7 mice (our unpublished results). In this vein, the combined 
use of subcutaneous and ICV administration of nusinersen may improve the therapeutic effects of this drug in 
SMA  myopathy41.
Materials and methods
Animals. Smn+/−;SMN2+/+;SMN∆7+/+, heterozygous knockouts for mouse Smn (FVB. Cg-
Tg[SMN2*delta7]4299Ahmb Tg[SMN2]89Ahmb Smn1tm1Msd/J, stock number 005025), which were pur-
chased from the Jackson Laboratory (Sacramento, USA), were crossed to generate Smn−/−;SMN2+/+;SMN∆7+/+ 
(SMN∆7) mice and Smn+/+;SMN2+/+;SMN∆7+/+ mice that were wild-type for Smn (WT). SMN∆7 mice exhibit a 
severe postnatal SMA phenotype with a mean lifespan of approximately 2 weeks69,70. Animal care and handling 
were performed in accordance with the Spanish legislation (Spanish Royal Decree 53/2013 BOE) and the guide-
lines of the European Commission for the Accommodation and Care of Laboratory Animals (revised in Appen-
dix A of the Council Directive 2010/63/UE). The experimental plan was approved by the Ethics Committee of 
the University of Cantabria and the Committee for Animal Care and Use of the University of Lleida. On P0, the 
identification of WT and SMN∆7 mice performed by genotyping with PCR. DNA was extracted from the tail, as 
previously  described69. Age-matched WT littermates of mutant animals were used as controls.
To investigate the effects of nusinersen (Spinraza) treatment in the αMNs of SMN∆7 mice, we used 32 ani-
mals (16 WT mice and 16 SMN∆7 mice) that were divided into four groups. WT and SMN∆7 mice were treated 
with 10 µl of Spinraza (Biogen) at a dose of 6.5 mg/kg (nusinersen group), or with 10 µl of a 0.9% saline solution 
(vehicle group). Spinraza or the vehicle was injected at the day of birth (P0) via ICV at the precise point indicated 
in Fig. 1A using a 10-µl syringe and a custom 33-gauge needle (Hamilton), as described  previously41. All mice 
were sacrificed at the late symptomatic neurodegenerative stage (P12)26,27.
Motor righting reflex test. To analyze the effect of nusinersen treatment on motor functions, we used the 
surface righting test (righting reflex), according to the protocol of Feather-Schussler and  Ferguson39. Briefly, this 
test assesses the motor capacity such that a mouse pup can stand up from a supine position. The average age for 
the rodent straightening reflex to appear is P5. As this test is a reflex, there is no learning component, and it can 
be repeated throughout the period of experimentation. This test consists of placing the pups face up on a cotton 
sheet or bench pad and keeping them in this position for 5 s. The pups are then released, and the time it takes to 
return to the prone position is recorded, as well as the direction of the correction (left or right). A total of 1 min 
is given for each test, if necessary. The test is repeated for a total of three trials.
Succinate dehydrogenase (SDH) assay. To investigate the effect of the ICV administration of nusin-
ersen on the phenotype type of TA muscle myofibers in the SMNΔ7 mouse, we used the histochemical SDH 
assay, a specific mitochondrial marker of myofiber oxidative activity. Thus, most SDH-positive myofibers corre-
spond to small type 1 myofibers, which have slow contraction and high aerobic metabolism. Less SDH-positive 
myofibers of type 2X of greater caliber are associated with faster contraction and more anaerobic muscle. Finally, 
type 2A myofibers have an intermediate signal and activity between type 1 and 2X  myofibers71. Briefly, transverse 
cryosections were incubated in an SDH reaction mixture (1.5 mM nitroblue tetrazolium, 5 mM EDTA, 48 mM 
succinic acid, 0.75 mM sodium azide, 30 mM methyl-phenylmethyl sulfate, and phosphate buffered pH 7). Dur-
ing the electron transfer from succinic acid to nitroblue tetrazolium by SDH, a color change occurs, the rate of 
which represents SDH activity. As controls, we used cryosections incubated in a medium lacking succinic acid. 
Then, the samples were air-dried and mounted, and images were captured with a microscope (Zeiss, Axioscop 
Plus) using 40 × or 63 × oil objectives. The morphometric analysis of myofiber diameter was performed on 
transversal cryosections of the TA muscle stained with the histochemical SDH assay. The measurement of the 
diameter of each myofiber in the field was performed on randomly collected microscope images using a 40 × 
objective and ImageJ software (National Institutes of Health). At least 100 myofibers per animal (n = 3, WT; n = 3, 
SMN∆7; and n = 3, nusinersen-treated SMN∆7 mice) were measured.
Immunofluorescence and confocal microscopy. For immunofluorescence analysis of αMNs at P12, 
4 mice per group (WT, SMN∆7 and nusinersen-treated SMN∆7 mice) were fixed by perfusion with 3.7% para-
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formaldehyde (freshly prepared) in phosphate-buffered saline (PBS) under deep anesthesia with pentobarbital 
(50 mg/kg). The spinal cords were rapidly dissected, removed, postfixed for 6 h and washed in PBS. Transverse 
sections (160-µm thick) of the spinal cord were obtained with a vibratome, and small tissue fragments from the 
anterior horn were dissected out. The samples were transferred to a drop of PBS on a positively charged slide 
(Superfrost Plus, Thermo Scientific, Germany), and squash preparations of dissociated MNs were generated fol-
lowing the previously reported  procedure43.
For muscle, tissue fragments of the TA were pinned to cork, immersed in ice-cold relaxing buffer (100 mM 
NaCl, 2 mM KCl, 2 mM  MgCl2, 6 mM  K3PO4, 1 mM EGTA, and 0.1% glucose; pH 7.0) and relaxed at 4 °C until 
fixed in 3.7%  paraformaldehyde72. Muscle fragments were cryoprotected in 15% and 30% sucrose in PBS (phos-
phate saline buffer: 137 mM NaCl, 2.7 mM KCl, 8 mM  Na2HPO4, and 2 mM  KH2PO4; pH 7.4) until they sank, 
embedded in Tissue-Tek OCT Compound (Sakura FineTek USA), and frozen on a chilled metal block in dry ice. 
Cryosections measuring 8 μm in thickness were mounted on SuperFrost slides and stored at − 80 °C until use.
For immunofluorescence, all samples were processed as described in Pena et al.43. Briefly, samples were 
treated with 0.5% Triton X-100 for 45 min and incubated for 3 h with the primary antibody containing at room 
temperature. Specific secondary antibody conjugated with FITC, Texas Red or Cy3, or Cy5 (diluted 1:75, Jackson, 
USA) were used. Some samples were counterstained with propidium iodide (PI) or Phalloidin-FITC. The slides 
were mounted with ProLong Anti-Fading Medium (Invitrogen).
We used an LSM510 (Zeiss, Germany) laser scanning microscope using a 63 × oil (1.4 NA) objective. To avoid 
overlapping signals, images were obtained by sequential excitation at 488 nm and 543 nm. The fluorescence pro-
files of confocal intensity signals across a line shown in Fig. S2 were generated using confocal images of double 
immunolabeled samples. Images were processed using Adobe Photoshop CS6 software.
The following primary antibodies were used for immunofluorescence: mouse monoclonal anti-SMN (diluted 
1:100, catalog no. 610646, BD Transduction Laboratories, USA); mouse monoclonal anti-TMG-cap (NA02A, 
Oncogene, USA); mouse monoclonal anti-fibrillarin (diluted 1:100, catalog no. ab4566, Abcam, USA); rabbit 
polyclonal anti-coilin (1:500, 204.10, Prof. A. Lamond, Dundee, UK); and goat polyclonal anti-choline acetyl-
transferase (ChAT) (1:200, AB144P, Millipore, MA, USA).
In situ hybridization and quantification. Fluorescence in  situ hybridization (FISH) was performed 
according to the protocol described by Narcís et al.27. Preparations of MNs were permeabilized with TBS-E-SDS 
for 15 min at 37 °C, washed three times in 6 × SSPE-0.1% Tween 20 for 15 min, and incubated with the probe 
containing tRNA for 3 h at 42  °C in a humidified chamber. An oligo(dT)(50)-mer, 5′-end-labeled with biotin 
(MWG-Biotech, Germany), was used as a probe for fluorescence in situ hybridization (FISH) to poly(A) RNA. 
The hybridization mixture contained 80 ng of oligo dT(50), 2 × SSC, 1 mg/ml tRNA, 10% dextran sulfate and 
25% formamide. After hybridization, preparations of MNs were washed in 6 × SSC for 15 min and then washed 
in 4 × SSC-0.1% Tween 20 for 15 min at room temperature. The hybridization signal was detected with FITC-
avidin for 30 min. All samples were mounted with Vectashield (Vector, USA).
The quantitative analysis of the proportion of SMN∆7 αMNs containing PARGs was performed in squash 
preparations processed for FISH with the poly(dT) probe. The proportion of neurons containing these granules 
was estimated by direct examination of the different focal planes throughout neuronal nuclei using a 40 × objec-
tive. Quantification was performed on at least 100 αMNs from WT (n = 4), SMN∆7 (n = 4) and nusinersen-treated 
SMN∆7 (n = 4) mice.
qRT‑PCR for relative gene expression analysis. For qRT-PCR, we used WT (n = 4), SMN∆7 (n = 4) 
and nusinersen-treated SMN∆7 (n = 4) mice. Mice were decapitated after being anesthetized, and the lumbar 
spinal cord was quickly removed and frozen in liquid nitrogen. RNA was isolated with TRIzol following the 
manufacturer’s instructions (Invitrogen, Carlsbad) and purified with the RNeasy kit (Qiagen, Hilden, Germany).
According to our laboratory  protocols27, 1 μg of RNA was reverse-transcribed to first-strand cDNA utilizing 
a High Capacity cDNA Reverse Transcription Kit (Life Technologies) using random hexamers as primers. The 
expression of the mRNA candidates ChAT and Chodl was determined by qRT-PCR using gene-specific SYBR 
Green-based primers (Invitrogen). The threshold cycle (Ct) for each well was determined and the results were 
normalized to Gapdh mRNA. Relative gene expression was calculated according to the 2-(ΔΔCt)  equation73. Each 
value in this work represents the mean ± SD of independent samples obtained under the same conditions and 
compared to two replicated qRT-PCR analyses. The SYBR Green-based specific primers for murine pre-RNAs 
analyzed were as follows: for the pre-mRNA of ChAT 5′-CTT GGG GCC AGT CTG ATA GC-3′ and 5′-GGA CAC 
ATG GCT AGA AGG GG-3′ and for the pre-mRNA of Chodl 5′-GCT GTT GTC TCC CGC ATC TT-3′ and 5′-AAG 
TGG AAG CGT TTG GGA TT-3′.
SDS‑PAGE and immunoblotting. Analysis of the level of SMN protein were performed according to 
the protocol described by Narcís et al. 27. Briefly, spinal cords and skeletal TA muscle samples from WT (n = 3), 
SMN∆7 (n = 3) and nusinersen-treated SMN∆7 (n = 4) mice were lysed at 4 °C in a buffer containing 50 mM 
Tris (pH 8), 150 mM NaCl, 2% Nonidet NP-40, 1 mM  MgCl2, 1 mM dithiothreitol, and 10% glycerol and sup-
plemented with EDTA-free complete protease inhibitor cocktail and PhosphoSTOP (Roche). Samples were soni-
cated and cleared by centrifugation at 14,000 rpm for 10 min at 4 °C. The proteins were separated on 4–20% 
NuPage TG SDS–PAGE gels (Invitrogen) and transferred to nitrocellulose membranes using standard proce-
dures. Mouse monoclonal anti-SMN (diluted 1:500) and rabbit polyclonal anti-Lamin A/C (diluted 1:1,000, 
generously donated by Prof. Gerace) were used. Protein bands were detected with an Odyssey Infrared-Imaging 
System (Li-Cor Biosciences) according to the Odyssey Western-Blotting Protocol. For the quantitative analysis 
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of the blots, ImageJ software was used (U.S. National Institutes of Health, Bethesda, Maryland, USA, https ://
image j.nih.gov/ij).
Statistical analysis. For comparisons among the experimental groups, data were analyzed using GraphPad 
Prism 7 software and PASW Statistics 22 (SPSS, Inc.) packages. Data are expressed as mean ± SD. The statistical 
analysis was assessed by one-way ANOVA or mixed-design two-way ANOVA (Split-Plot ANOVA), followed by 
the Bonferroni post hoc test (SPSS) or Student’s t test (GraphPad). In all cases, differences were considered to be 
statistically significant if p < 0.05.
Received: 27 February 2020; Accepted: 8 June 2020
References
 1. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
 2. Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265–269. https 
://doi.org/10.1038/ng079 7-265 (1997).
 3. Burghes, A. H. M. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor 
neurons sick?. Nat. Rev. Neurosci. 10, 597–609. https ://doi.org/10.1038/nrn26 70 (2009).
 4. Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy 
gene SMN2. Hum. Mol. Genet. 8, 1177–1183. https ://doi.org/10.1093/hmg/8.7.1177 (1999).
 5. Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(−/−) mice 
and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333–339 (2000).
 6. Lorson, C. L. et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 19, 63–66. https ://
doi.org/10.1038/ng059 8-63 (1998).
 7. Cho, S. & Dreyfuss, G. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. 
Genes Dev. 24, 438–442. https ://doi.org/10.1101/gad.18849 10 (2010).
 8. Feldkötter, M. et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier 
testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70, 358–368. https ://doi.org/10.1086/33862 7 
(2002).
 9. Cuscó, I. et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial vari-
ability in siblings. J. Neurol. 253, 21–25. https ://doi.org/10.1007/s0041 5-005-0912-y (2006).
 10. Wirth, B. et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spi-
nal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am. J. Hum. Genet. 64, 1340–1356. 
https ://doi.org/10.1086/30236 9 (1999).
 11. Wirth, B. et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. 
Hum. Genet. 119, 422–428. https ://doi.org/10.1007/s0043 9-006-0156-7 (2006).
 12. Pellizzoni, L., Yong, J. & Dreyfuss, G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298, 
1775–1779. https ://doi.org/10.1126/scien ce.10749 62 (2002).
 13. Meister, G. et al. A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs. Nat. Cell Biol. 3, 
945–949. https ://doi.org/10.1038/ncb11 01-945 (2001).
 14. Matera, A. G. & Wang, Z. A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 15, 108–121. https ://doi.org/10.1038/nrm37 
42 (2014).
 15. Gall, J. G. Cajal bodies: the first 100 years. Annu. Rev. Cell Dev. Biol. 16, 273–300. https ://doi.org/10.1146/annur ev.cellb io.16.1.273 
(2000).
 16. Machyna, M., Heyn, P. & Neugebauer, K. M. Cajal bodies: where form meets function. Wiley Interdiscip. Rev. RNA 4, 17–34. https 
://doi.org/10.1002/wrna.1139 (2013).
 17. Sawyer, I. A., Hager, G. L. & Dundr, M. Specific genomic cues regulate Cajal body assembly. RNA Biol. https ://doi.org/10.1080/15476 
286.2016.12436 48 (2016).
 18. Lafarga, M., Casafont, I., Bengoechea, R., Tapia, O. & Berciano, M. T. Cajal’s contribution to the knowledge of the neuronal cell 
nucleus. Chromosoma 118, 437–443 (2009).
 19. Frey, M. R. & Matera, A. G. RNA-mediated interaction of Cajal bodies and U2 snRNA genes. J. Cell Biol. 154, 499–509. https ://
doi.org/10.1083/jcb.20010 5084 (2001).
 20. Schul, W., van Driel, R. & de Jong, L. Coiled bodies and U2 snRNA genes adjacent to coiled bodies are enriched in factors required 
for snRNA transcription. Mol. Biol. Cell 9, 1025–1036. https ://doi.org/10.1091/mbc.9.5.1025 (1998).
 21. Wang, Q. et al. Cajal bodies are linked to genome conformation. Nat. Commun. 7, 10966. https ://doi.org/10.1038/ncomm s1096 6 
(2016).
 22. Raska, I. et al. Association between the nucleolus and the coiled body. J. Struct. Biol. 104, 120–127 (1990).
 23. Machyna, M. et al. The coilin interactome identifies hundreds of small noncoding RNAs that traffic through Cajal bodies. Mol. 
Cell 56, 389–399. https ://doi.org/10.1016/j.molce l.2014.10.004 (2014).
 24. Trinkle-Mulcahy, L. & Sleeman, J. E. The Cajal body and the nucleolus: “In a relationship” or “It’s complicated”?. RNA Biol. https 
://doi.org/10.1080/15476 286.2016.12361 69 (2016).
 25. Tapia, O. et al. Reorganization of Cajal bodies and nucleolar targeting of coilin in motor neurons of type I spinal muscular atrophy. 
Histochem. Cell Biol. 137, 657–667. https ://doi.org/10.1007/s0041 8-012-0921-8 (2012).
 26. Tapia, O. et al. Cellular bases of the RNA metabolism dysfunction in motor neurons of a murine model of spinal muscular atrophy: 
Role of Cajal bodies and the nucleolus. Neurobiol. Dis. 108, 83–99. https ://doi.org/10.1016/j.nbd.2017.08.004 (2017).
 27. Narcís, J. O. et al. Accumulation of poly(A) RNA in nuclear granules enriched in Sam68 in motor neurons from the SMNΔ7 mouse 
model of SMA. Sci. Rep. 8, 9646. https ://doi.org/10.1038/s4159 8-018-27821 -3 (2018).
 28. Caillet-Boudin, M.-L. et al. Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front. 
Mol. Neurosci. 6, 57. https ://doi.org/10.3389/fnmol .2013.00057 (2014).
 29. Singh, N. K., Singh, N. N., Androphy, E. J. & Singh, R. N. Splicing of a critical exon of human survival motor neuron is regulated 
by a unique silencer element located in the last intron. Mol. Cell Biol. 26, 1333–1346. https ://doi.org/10.1128/MCB.26.4.1333-
1346.2006 (2006).
 30. Hua, Y. et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. 
Hum. Genet. 82, 834–848. https ://doi.org/10.1016/j.ajhg.2008.01.014 (2008).
 31. Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 
1634–1644. https ://doi.org/10.1101/gad.19413 10 (2010).
12
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10738  | https://doi.org/10.1038/s41598-020-67569-3
www.nature.com/scientificreports/
 32. Rigo, F. et al. Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing 
oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55. https ://doi.org/10.1124/jpet.113.21240 7 
(2014).
 33. Talbot, K. & Tizzano, E. F. The clinical landscape for SMA in a new therapeutic era. Gene Ther. https ://doi.org/10.1038/gt.2017.52 
(2017).
 34. Bennett, C. F., Krainer, A. R. & Cleveland, D. W. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu. Rev. 
Neurosci. 42, 385–406. https ://doi.org/10.1146/annur ev-neuro -07091 8-05050 1 (2019).
 35. Wood-Allum, C. & Shaw, P. J. Motor neurone disease: a practical update on diagnosis and management. Clin. Med. 10, 252–258 
(2010).
 36. Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. 
Sci. Transl. Med. 3, 72ra18. https ://doi.org/10.1126/scitr anslm ed.30017 77 (2011).
 37. Sahashi, K. et al. TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals. Genes Dev. 26, 1874–1884. 
https ://doi.org/10.1101/gad.19741 8.112 (2012).
 38. Sleigh, J. N. et al. Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular 
atrophy. Hum. Mol. Genet. 23, 855–869. https ://doi.org/10.1093/hmg/ddt47 7 (2014).
 39. Feather-Schussler, D. N. & Ferguson, T. S. A battery of motor tests in a neonatal mouse model of cerebral palsy. J. Vis. Exp. https 
://doi.org/10.3791/53569 (2016).
 40. Dubowitz, V. & Sewry, C. Muscle Biopsy: A Practical Approach (Elsevier, Philadelphia, 2007).
 41. Hua, Y. et al. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic 
mouse models. Genes Dev. 29, 288–297. https ://doi.org/10.1101/gad.25664 4.114 (2015).
 42. Jablonka, S. et al. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model 
for spinal muscular atrophy type III. Hum. Mol. Genet. 9, 341–346. https ://doi.org/10.1093/hmg/9.3.341 (2000).
 43. Pena, E. et al. Neuronal body size correlates with the number of nucleoli and Cajal bodies, and with the organization of the splicing 
machinery in rat trigeminal ganglion neurons. J. Comp. Neurol. 430, 250–263 (2001).
 44. Lafarga, M., Tapia, O., Romero, A. M. & Berciano, M. T. Cajal bodies in neurons. RNA Biol. https ://doi.org/10.1080/15476 
286.2016.12313 60 (2017).
 45. Liu, Q. & Dreyfuss, G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15, 3555–3565 (1996).
 46. Navascues, J. et al. Targeting SMN to Cajal bodies and nuclear gems during neuritogenesis. Chromosoma 112, 398–409. https ://
doi.org/10.1007/s0041 2-004-0285-5 (2004).
 47. Zhang, Z. et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. 
Cell 133, 585–600. https ://doi.org/10.1016/j.cell.2008.03.031 (2008).
 48. Bäumer, D. et al. Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS 
Genet. 5, e1000773. https ://doi.org/10.1371/journ al.pgen.10007 73 (2009).
 49. Lotti, F. et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151, 440–454. https ://doi.
org/10.1016/j.cell.2012.09.012 (2012).
 50. Doktor, T. K. et al. RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of 
U12-dependent introns. Nucleic Acids Res. 45, 395–416. https ://doi.org/10.1093/nar/gkw73 1 (2017).
 51. Jangi, M. et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. 
Proc. Natl. Acad. Sci. 114, E2347–E2356. https ://doi.org/10.1073/pnas.16131 81114 (2017).
 52. Zhong, Z. et al. Chondrolectin mediates growth cone interactions of motor axons with an intermediate target. J. Neurosci. 32, 
4426–4439. https ://doi.org/10.1523/JNEUR OSCI.5179-11.2012 (2012).
 53. Bernabò, P. et al. In vivo translatome profiling in spinal muscular atrophy reveals a role for SMN protein in ribosome biology. Cell 
Rep. 21, 953–965. https ://doi.org/10.1016/j.celre p.2017.10.010 (2017).
 54. Peters, A., Palay, S. L. & deF Webster, H. The Fine Structure of the Nervous System: Neurons and Their Supporting Cells 3rd edn. 
(Oxford University Press, New York, 1991).
 55. Casafont, I., Berciano, M. T. & Lafarga, M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 
and PABPN1 in sensory ganglia neurons. Neurotox. Res. 17, 167–178 (2010).
 56. Palanca, A., Casafont, I., Berciano, M. T. & Lafarga, M. Proteasome inhibition induces DNA damage and reorganizes nuclear archi-
tecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol. Life Sci. 71, 1961–1975. https ://doi.org/10.1007/
s0001 8-013-1474-2 (2014).
 57. Hamilton, G. & Gillingwater, T. H. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19, 40–50. https 
://doi.org/10.1016/j.molme d.2012.11.002 (2013).
 58. Chaytow, H., Huang, Y. T., Gillingwater, T. H. & Faller, K. M. E. The role of survival motor neuron protein (SMN) in protein 
homeostasis. Cell Mol. Life Sci. https ://doi.org/10.1007/s0001 8-018-2849-1 (2018).
 59. Porensky, P. N. et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. 
Mol. Genet. 21, 1625–1638. https ://doi.org/10.1093/hmg/ddr60 0 (2012).
 60. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug 
Discov. 11, 125–140. https ://doi.org/10.1038/nrd36 25 (2012).
 61. Lafarga, M., Andres, M. A., Berciano, M. T. & Maquiera, E. Organization of nucleoli and nuclear bodies in osmotically stimulated 
supraoptic neurons of the rat. J. Comp. Neurol. 308, 329–339. https ://doi.org/10.1002/cne.90308 0302 (1991).
 62. Baltanás, F. C. et al. Purkinje cell degeneration in pcd mice reveals large scale chromatin reorganization and gene silencing linked 
to defective DNA repair. J. Biol. Chem. 286, 28287–28302. https ://doi.org/10.1074/jbc.M111.24604 1 (2011).
 63. Klingauf, M., Stanek, D. & Neugebauer, K. M. Enhancement of U4/U6 small nuclear ribonucleoprotein particle association in Cajal 
bodies predicted by mathematical modeling. Mol. Biol. Cell 17, 4972–4981. https ://doi.org/10.1091/mbc.E06-06-0513 (2006).
 64. Novotný, I. et al. In vivo kinetics of U4/U6·U5 tri-snRNP formation in Cajal bodies. Mol. Biol. Cell 22, 513–523. https ://doi.
org/10.1091/mbc.E10-07-0560 (2011).
 65. Kühn, U. & Wahle, E. Structure and function of poly(A) binding proteins. Biochim. Biophys. Acta 1678, 67–84. https ://doi.
org/10.1016/j.bbaex p.2004.03.008 (2004).
 66. Shan, P. et al. SIRT1 functions as a negative regulator of eukaryotic poly(A)RNA transport. Curr. Biol. 27, 2271-2284.e5. https ://
doi.org/10.1016/j.cub.2017.06.040 (2017).
 67. Hett, A. & West, S. Inhibition of U4 snRNA in human cells causes the stable retention of polyadenylated pre-mRNA in the nucleus. 
PLoS ONE 9, e96174. https ://doi.org/10.1371/journ al.pone.00961 74 (2014).
 68. Novotný, I. et al. SART3-dependent accumulation of incomplete spliceosomal snRNPs in Cajal bodies. Cell Rep. https ://doi.
org/10.1016/j.celre p.2014.12.030 (2015).
 69. Tarabal, O. et al. Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy. J. Neuro-
pathol. Exp. Neurol. 73, 519–535. https ://doi.org/10.1097/NEN.00000 00000 00007 4 (2014).
 70. Le, T. T. et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice 
with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845–857. https ://doi.org/10.1093/hmg/
ddi07 8 (2005).
 71. Talbot, J. & Maves, L. Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for suscep-
tibility and resistance to muscle disease. Wiley Interdiscip. Rev. Dev. Biol. 5, 518–534. https ://doi.org/10.1002/wdev.230 (2016).
13
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:10738  | https://doi.org/10.1038/s41598-020-67569-3
www.nature.com/scientificreports/
 72. Gokhin, D. S. et al. Tropomodulin isoforms regulate thin filament pointed-end capping and skeletal muscle physiology. J. Cell Biol. 
189, 95–109. https ://doi.org/10.1083/jcb.20100 1125 (2010).
 73. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. 
Methods 25, 402–408. https ://doi.org/10.1006/meth.2001.1262 (2001).
Acknowledgements
The authors wish to thank Raquel García-Ceballos for technical assistance and Alfonso Nieva for video editing. 
We are also grateful to Prof. A. I. Lamond (University of Dundee, UK) for anti-coilin antibody (204.10) and Prof. 
Larry Gerace (The Scripps Research Institute, La Jolla, USA) for anti-LaminA/C antibody. The authors are also 
indebted to Prof. Josep E. Esquerda for critical reading of the manuscript and helpful suggestions. This work was 
supported by the following grants: Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegen-
erativas (CIBERNED, CB06/05/0037) Spain; Instituto de Investigación Sanitaria Valdecilla (IDIVAL, Next-Val 
17/22), Santander, Spain; and Spanish Ministerio de Ciencia, Innovación y Universidades cofinanced by Fondo 
Europeo de Desarrollo Regional (FEDER) (RTI2018-099278-B-I00).
Author contributions
O.T., M.L., M.T.B. and J.C. conceived and designed the experiments. M.T.B., A.P.B., A.M.S., O.T., M.L., and J.C. 
performed the experiments and analyzed the data. O.T., M.L., M.T.B. and J.C.R.R. wrote the paper.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-67569 -3.
Correspondence and requests for materials should be addressed to O.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
